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Doctoral Thesis: Introductory Summary 
Skin diseases are common throughout society and up to 60% of individuals are affected at any 
point in time (1). In general, they represent the fourth most common cause of non-fatal disease, and 
due to their morbidity, the burden of skin diseases is high (2, 3). Many skin diseases like psoriasis, 
chronic urticaria (CU), and alopecia are chronic in nature and require professional treatment. 
Psoriasis affects about 100 million individuals worldwide, and its prevalence in developed countries 
ranges from 1.5% to 5.0% (4), with a reported prevalence of 2.5% for Germany (5). In addition to 
many other comorbidities like psoriatic arthritis and cardio metabolic diseases, psoriasis is also 
associated with substantial mental burden (6). In 2014, psoriasis was identified as one of the five 
most impairing non‐communicable diseases by the World Health Assembly (WHA) (7). 
Subsequently, the World Health Organization (WHO) issued and released the global report on 
psoriasis in 2016, which sheds light on the comprehensive burden of psoriasis (8). 
Regarding the mental burden of skin diseases in general, a European study among 13 countries 
showed that people with skin diseases have an approximately twofold risk for depression and 
anxiety disorder compared to healthy individuals (9). For individuals with psoriasis, the risk is three 
times higher. Furthermore, several studies have found psoriasis to be associated with addictions 
(10–12). A meta-analysis suggested that patients with psoriasis have a pooled Odds Ratio (OR) of 
1.78 for smoking in comparison to healthy controls (10). A systematic review suggested that alcohol 
consumption is higher among patients with psoriasis (11). However, evidence about other 
addictions hardly exists. Thus far, one monocentric study among 102 psoriasis patients indicated 
higher values for compulsive gambling and drug abuse in addition to a higher prevalence of 
smoking and alcohol dependency in patients with psoriasis compared to the general population (12). 
Other addictions, such as Internet addiction, have not yet been studied.  
Along with the mental burden of the disease, the WHA and WHO emphasized the occurring 
stigmatization of psoriasis (7, 8). To illustrate the need for action, the WHO provided the example 
of a man who was ejected from a public pool due to other guest complaining about his psoriatic 
skin lesions. Despite knowing that the lesions were non-contagious, the lifeguards requested him to 
leave to satisfy the other guests (8). As psoriasis can cover any amount of body surface and any 
body localization including the genital and anal area, social impairments can occur in various 
situations, including very intimate situations such as sexual contact. While patients with psoriasis 
in general tend to have impaired quality of life and tend to avoid sexual contact, patients with genital 
8
involvement report even poorer outcomes in both (13–15). Prevalence estimates for genital 
involvement are highly heterogeneous and range from 7% to 42% of all patients with psoriasis (16). 
Furthermore, 60% of affected patients from a French study indicated that they were aware of the 
genital involvement of their psoriasis; however, this genital involvement was not previously 
examined by an health care professional (HCP) (17). Affected individuals often hide this additional, 
personal, and very intimate burden rather than discuss it with their HCP, which could lead to an 
underestimation of the prevalence of genital psoriasis (17). However, despite effective treatments 
being available (15, 18), still many individuals with psoriasis do not seek medical care at all and 
therefore do not receive appropriate treatment (19). 
Within their report, the WHO emphasized the importance of people-centered care approaches, 
especially for chronic skin diseases like psoriasis (8). The corresponding call for action addressing 
governments and policy makers included early detection as well as adequate medical treatment (8). 
Addressing HCPs, the WHO further emphasized the detection of psoriasis and comorbidities in all 
medical disciplines and the need to provide comprehensive care in multidisciplinary teams of 
specialists (e.g. dermatologists, rheumatologists, psychologists) using a holistic approach (8, 20). 
Another call for action of the WHA resolution addressed all member states directly and demanded 
to raise awareness for the psychosocial burden of psoriasis (7). Therefore, prevention programs 
should be implemented to reduce stigmatization, which had been identified as a major factor for 
mental burden in chronic skin diseases. These programs ideally have the potential to be extended 
to other visible skin manifestations like atopic dermatitis, alopecia, and CU, which all are 
accompanied by a substantial burden (2, 21–23). One example for the implementation of this 
demand is a nationwide task force founded by the Federal Ministry of Health (Bundesministerium 
für Gesundheit; BMG) in Germany, which aimed to widen the horizon of dermatological research 
and focus to not only include psoriasis, but include all visible skin diseases and their potential 
stigmatization (24, 25).  
Subsequently, the aim of this doctoral thesis was to follow the WHO’s call for action and to 
further characterize the mental burden of chronic skin diseases. This thesis therefore focused on (I) 
addictions in psoriasis, especially Internet addiction, using both patient-physician settings and a 
people-centered care approach, (II) genital psoriasis and sexual avoidance, and (III) stigmatization 
of people with alopecia as part of a nationwide BMG project and as an outlook for diseases other 
than psoriasis. 
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Psoriasis and addictions: assessing mental health in a cross-sectional study across Germany 
(Appendix I)  
While many studies suggested a high prevalence of alcohol dependency and cigarette smoking 
in patients with psoriasis (9–11, 26, 27), Zink et al. performed the first study that investigated further 
addictions in a single-center study and revealed a high positive screening rate for compulsive 
gambling and drug abuse in 102 patients with psoriasis (12). Subsequently, the aim of this study 
was to estimate the prevalence of six common addictions (smoking, alcohol, gambling, Internet, 
food, and drugs) among patients with psoriasis to generate findings in a multi-center approach 
across Germany. Additionally, clinical factors associated with the occurrence of the respective 
addictions were to be identified, which were thought to function as indicators of poor mental health 
in time-restricted clinical practice.  
 In this cross-sectional study, 32 dermatological practices and 4 dermatological clinics across 
south-western Germany recruited a total of 502 patients (mean age: 49.7 ± 14.6 years; 43.4% 
women) between September 2018 and November 2019. Screenings for all mental health outcomes 
were performed using standardized and validated questionnaires and a one-question item on tobacco 
smoking. First findings by Zink et al. were confirmed, and positive screening rates for pathological 
gambling and drug abuse exceeded those reported for the general population (gambling: 1.2% vs. 
0.2% (28); drug abuse: 6.0% vs. 3.2%-5.2% (29)). Furthermore, the rate of positive screenings 
regarding Internet addiction was higher than in a representative sample of German adolescents 
(3.8% vs. 3.2%) (30). This rate was surprisingly high considering that Internet addiction decreases 
with rising age (31, 32) and that the participants’ mean age in this study (49.7 years) was 
considerably higher than the participants’ mean age in the comparison study (14.9 years). With 
limited time per patient in clinical practice, the second aim of this study was to identify certain 
influencing factors for the occurrence of the respective addictions. Younger age was associated with 
a higher chance for the occurrence of most addictions. Other associated factors were however 
inconsistent. Therefore, standardized and not too time-consuming assessments of mental 
comorbidities might be of high value for future psoriasis care.  
This study was also used to test the hypothesis of a pervious published study (12). As the 
‘Psoriasis Area and Severity Index’ (PASI), the most common used measurement to assess the 
characteristics of psoriasis, only represents disease severity at one time point, it might not be 
conclusive for a lifetime burden, which potentially cumulate throughout patients’ medical history 
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(33, 34). Therefore, we aimed to determine the association of patients highest ever documented 
PASI, the ‘PeakPASI’, and patient reported outcomes. 
PeakPASI: A new measurement tool in psoriasis care 
All participating dermatologists were asked to provide the PeakPASI for each patient. Overall, 
PeakPASI values for 398 patients were recorded. To assess differences in the study population, two 
PeakPASI thresholds were chosen: ≥10, based on clinical practice and ≥13.6, based on a median 
split. According to the median split-based analyses, patients having a higher PeakPASI were more 
likely to show higher ‘Dermatology Life Quality Index’ (DLQI) values, indicating higher disease 
related impairment of quality of life, and lower values of heuristic happiness. Even though, the 
PeakPASI holds some limitations, this letter represents the first report trying to evaluate its potential 
and to improve comprehensive and patient-centered disease characterization by including a measure 
for lifetime disease burden. 
As a result of the main subject of this study, Internet addiction was found to be of enormous 
interest. This rising phenomenon of our century was only recently added to the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as the most potent problem in need 
of further research and it is showing rising trends with the omnipresence of the Internet and online 
possibilities (35, 36). As this first study was carried out in a typical medical setting and only 
considered patients who were in medical care, the study partially neglected the principle of people-
centered care demanded by the WHO. Therefore, the second study of the Ph.D. thesis was 
performed to access individuals who may be neglected by more conventional study methodologies. 
This study also investigated Internet addiction in conjunction with established addictive 
comorbidities (alcohol dependency and tobacco smoking) in a more diverse sample of individuals 
with psoriasis. 
Always Online? Internet Addiction and Social Impairment in Psoriasis across Germany 
To reach affected individuals, a cross-sectional online survey was designed in collaboration with 
the online self-help organization ‘Psoriasis Netz,’ which provides up-to-date information on 
psoriasis and related topics. The questionnaire was shared via the self-help organization’s 
newsletter, webpage, and social media channels, including Facebook and Twitter. Additionally, it 
was distributed via the patient organization ‘Farbenhaut’ and a campaign of the Association of the 
German Dermatologists (Berufsverband der Deutschen Dermatologen; BVDD) called ‘Bitte 
berühren.’ This method was used to reach individuals who (i) were affected by psoriasis and (ii) 
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felt the need for further support and therefore turned to a respective entity. To further emphasize 
the people-centered nature of this investigation and acknowledge potential psychological 
components of Internet addictions (37), information about the social impairment of participants as 
well as activities avoided due to psoriasis was collected.  
Overall, 460 individuals (mean age: 45.9±13.7 years; 62.4% women) participated in this study. 
Of these, 22.8% indicated to do not utilize medical health care at the time of study participation and 
88.3% stated to be at least rarely socially impaired. When considering leisure activities, participants 
with psoriasis most frequently stated swimming as the activity from which they abstained the most. 
As this is in line with first findings reported in the 1980’s (38), these results emphasize the need for 
interventions such as those planned and conducted by the aforementioned BMG initiative and the 
importance of reducing stigmatization (24). Free text answers like avoiding ‘Any activity requiring 
short clothing’ (woman; 21 years) or ‘Roughhousing with my son’ (man; 34 years) furthermore 
underlined the substantial individual burden under which affected individuals often suffer. 
The positive screening rate for Internet addiction was 8.5%. This was substantially higher than 
the positive screening rates reported in the first conducted study and in the literature on the German 
general population (3.8% vs. 1.0-1.5% (31)). As this study was based on an online approach, one 
could have anticipated higher positive screening rates, as affected individuals without Internet 
access were not able to participate. However, a prior study on 245 healthy individuals recruited in 
an online setting also revealed a prevalence of only 1.2% (39), which increases the meaningfulness 
of our data among individuals with psoriasis.  
Furthermore, 40.0% of participants had positive screenings for depression, 17.1% for alcohol 
dependency, and 32.6% for daily smoking. When compared to the first study of this thesis and to 
the general population, respectively, results for smoking were comparable to the results in psoriasis 
patients in clinics and practices (32.6% vs. 30.3% vs. 15.1% (29)). In contrast, alcohol dependency 
was found to be more prevalent than in psoriasis patients reported before and the general population 
(17.1% vs. 8.6% vs. 3.1% (29)). The positive screening rate of depression slightly exceeded 
previous questionnaire-based findings among patients with psoriasis (40.0% vs. 13.8-39.2% (27)).  
While the approach of this study mainly targeted people who subscribed to newsletters or social 
media channels of certain webpages or who visited the self-help organization’s website during the 
study period, another online study that included short versions of screening questionnaires for 
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Internet addiction and depression was conducted. As many individuals search for health-related 
information using search engines (40–43) or social media (44), we decided to target individuals 
who recently searched for psoriasis or CU using advertisements on Google and Facebook. People 
with CU were also included in the study, as it is an additional chronic inflammatory skin disease 
that affects 0.5% of the general population in Europe (45) and is also accompanied by a high mental 
burden (21, 22). No data on Internet addiction was available for CU so far.  
People-centered care for psoriasis and urticaria: Are we overlooking Internet addiction while 
only considering patients and physician settings? 
This cross-sectional study comprises self-reported data from individuals with psoriasis and CU 
living in Germany using an online survey advertised via Facebook and Google from December 
2018 to January 2019.  
Overall, 1,686 participants (mean age: 36.9 ± 12.9 years; 74.0% women; 38.5% having 
psoriasis) were included in this study. More than half of the participants (54.7%) were currently not 
receiving medical care for their skin disease, with substantially more individuals with CU currently 
not utilizing medical care (60.3% vs. 45.9%; p<0.001). This proportion was considerably higher 
than in the third study of this thesis. Overall, 16.0% of participants were screened positive for 
Internet addiction. This positive screening rate again exceeded that of the online study among 
individuals reached via self-help groups for psoriasis (8.5%) as well as the positive screening rate 
among the multi-center study of patients with psoriasis (3.8%) and that of a representative sample 
of more than 8,130 individuals living in Germany (1.0-1.5%) (31). The inherent characteristics of 
an online approach might explain the higher positive screening rates in this sample and the sample 
of participants from an online self-help group. This potential effect, however, was as previously 
mentioned partly invalidated by Eichelberg et al., who found a prevalence for Internet addiction of 
only 1.2% among regular Internet users who were recruited, among others, from Facebook (39). 
This prevalence in turn does not exceed the results for the general German population, which might 
indicate that individuals with chronic skin manifestation are more likely to be affected by Internet 
addiction. A comparison of the positive screening rates in the three conducted studies furthermore 
suggests that individuals reached online might have a greater disease burden than those individuals 
seen in dermatological clinics and practices.  
The results illustrate that the mental burden of individuals affected by psoriasis is high and that 
addictions, especially Internet addiction, are common among affected individuals. However, this 
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already high burden of disease increases when the genital area of individuals is affected (13–15, 
46). Meanwhile, information on affected individuals outside of a conventional patient-physician 
setting is nonexistent. Furthermore, previous studies focused on the presence of intimacy avoidance 
without further qualitative analyses of respective reasons for avoidance. For example, a European 
cross-sectional study used only one question within the DLQI, stating ‘Over the last week, how 
much has your skin caused any sexual difficulties?’ and thus neglecting individual reasons for 
avoidance (9). Subsequently, the aims of the next study were to investigate the occurrence of genital 
psoriasis in a non-clinical setting and to determine factors related to the avoidance of sexual 
activities due to psoriasis. 
Genital Psoriasis and Associated Factors of Sexual Avoidance – A People-centered Cross-
sectional Study in Germany 
This article was published in Acta Dermato-Venereologica (ISI Citation Report 2019: Impact factor: 
4.016, Ranking: 7/68 [Dermatology]), where it was selected as a ‘research highlight of the month,’ and 
subsequently featured in their monthly newsletter (05/2020). The recruitment was carried out mostly 
via the patient self-help organization ‘Psoriasis-Netz’ and other institutions from March to June 
2019 using a similar methodology as the one described in the second project of this thesis. 
Overall, 344 individuals with psoriasis participated (mean age: 44.6 ± 13.2 years; 59.3% women). 
Of those, 83 (24.1%) did not currently utilize medical care and 198 (57.6%) stated that their genital area 
was affected. Compared to the prevalence reported in the literature (7-42%) (16), the occurrence of 
genital psoriasis was considerably higher in this study. In our study, individuals with genital psoriasis 
also more frequently reported pain (58.6% vs. 26.0%; p<0.001) and avoidance of sexual activities 
because of their psoriasis (74.2% vs. 52.7%; p<0.001) than those without genital involvement. In line 
with the limited preexisting literature (46, 13), the most common reason for avoiding sexual activities 
was shame, followed by pain and the fear of rejection. However, the presence of shame as the most 
common category implies that focusing on the stigmatization of skin lesions, especially in areas that 
highly affect individuals’ private life, might be beneficial for future people-centered care in psoriasis. 
Additionally, this study underlined the role of patient organizations in reaching out to highly vulnerable 
patient groups and individuals who do not seek medical help while promoting people-centered care. 
Finally, as an outlook for skin manifestations which should be further considered with regard to 
stigmatization and social withdrawal and as part of the aforementioned BMG-project (24), a 
systematic review on stigmatization in individuals with alopecia was conducted. 
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Stigmatization caused by hair loss – a systematic literature review (Appendix II) 
The aim of this additional paper in the scope of the thesis was to systematically summarize 
existing literature on the stigmatization of hair loss. Alopecia can be present as a symptom due to 
different pathogeneses and has varying severities (47–49). The most common forms of alopecia are 
androgenetic alopecia and alopecia areata (47). Additionally, hair loss is a common side effect of 
cancer treatments (49). According to the WHA resolution (7), psoriasis was selected as a model 
disease for planning interventions, which would then to be expanded to include other skin diseases. 
This literature review generated significant attention within the BMG’s project initiative, as it was 
the first review on further dermatological diseases to be conducted, finished, and published.  
Stigmatization describes a phenomenon that excludes affected individuals from total social 
acceptance (50). This problem can be triggered by the patients themselves (internal stigma) or be 
induced by their environment (external stigma) (50, 51). With regard to the social stigmatization of 
dermatological diseases, society’s point of view may be biased. While analyzing dermatologic 
findings among all-time top 10 American film villains and heroes, it appeared that substantial skin 
alterations were only present in villains (52). Subsequently, three out of ten villains showed 
substantial signs of alopecia, and this characterization of evil characters using alopecia dates as far 
back as 1921 in the film Nosferatu (53). Further examples for notable alopecic villains include Dr. 
Hannibal Lecter (The Silence of the Lambs; 1991), Dr. Evil (Austin Powers in Goldmember; 2002), 
and Lord Voldemort (Harry Potter; 2005-2011). While this association is only exemplary, it might 
contribute to prejudice and stigmatization, which in turn can lead to reduced mental health and 
severely impair the quality of life of affected individuals (25, 54). To generate evidence-based 
knowledge about stigmatization in hair loss, the presented systematic review was planned 
thoroughly in accordance with the respective ‘Preferred Reporting Items for Systematic reviews 
and Meta-analyses report’ (PRISMA) (55) and ‘Meta-Analysis of Observational Studies in 
Epidemiology’ (MOOSE) guidelines (56), and was registered within the PROSPERO database 
(Identification number: CRD42019122966) (57). 
Within four databases on medical and psychological scientific literature, 98 publications were 
identified and entered the screening. After reviewing the publications, 11 articles were included in 
the review. The identified studies showed a high degree of heterogeneity. Five articles investigated 
therapy induced alopecia after preexisting cancer, four androgenetic alopecia, three alopecia areata, 
and one diffuse alopecia. Only four studies shared a common questionnaire for the quantification 
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of stigmatization; the ‘Hairdex’ (58). In combination with the high heterogeneity and partly flawed 
methodological approaches by different authors, evidence on stigmatization due to alopecia was 
weak and difficult to compare. Single studies, however, stated perceived stigma of hair loss to be 
similar to the stigma of psychiatric conditions (59) and more severe than that of vitiligo (60). 
Although the resulting psychological stress is very high for those affected, stigmatization is often 
considered as one of many factors that impair quality of life. Overall, the review showed that 
specific studies on stigmatization in hair loss are rare and that longitudinal studies are non-existent, 
although they are strongly recommended.  
In summary, this Ph.D. thesis contributes to the fundamental characterization of the mental 
burden of chronic skin diseases, with a focus on psoriasis. It introduced Internet addiction as a 
possible addictive comorbidity and demonstrated high impairment in chronic skin diseases, 
particularly in genital psoriasis. Future studies should seek to validate these findings using claims 
data or suitable control groups. Standardized routine screening could be introduced to detect 
potential mental health impairments. Additionally, the thesis introduced a measure for disease 
severity beyond the conventional PASI, the PeakPASI. Even though, it includes limitations, this 
additional measure has the potential to better characterize disease burden that might accumulate 
throughout the disease history. Furthermore, the studies of this thesis represent one of the first 
approaches that focused on people-centered health care in chronic skin diseases as demanded by 
the WHO. Individuals reached using people-centered approaches showed a substantially higher rate 
of positive screenings for mental comorbidities than participants recruited from a traditional 
medical setting. Outreach programs and patient-journey approaches that are personalized and that 
contact affected individuals in the context of their everyday lives represent a highly promising 
approach when considering the possibilities of mental burden reduction in individuals affected by 
chronic skin diseases. Moreover, by exploring the stigmatization of alopecia, the thesis included 
evidence-based groundwork on another highly stigmatized chronic skin disease. Altogether, the 
thesis illustrates how chronic skin disorders can influence mental health and that further information 
on possible psychological comorbidities, like addictions, needs to be covered in future research 
including patient- and people-centered health care approaches. 
Specification of the personal contribution 
For the first study and Appendix I, I was responsible for the conceptual design, adaptation 
according to the comments from all co-authors and my thesis advisory committee, designing a 
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suitable data protection model, preparing and reaching an ethical approval, and contacting over 200 
dermatologists. Furthermore, contracts with all 35 centers had to be implemented. I coordinated all 
reception of data, payments, data digitalization and validation, data analysis, and preparation of the 
first manuscript. Lastly, all coauthors revised the manuscript and I submitted it. For the first 
manuscript, Dr. Linda Tizek and I handled all data analysis and writing likewise, wherefore we 
shared the first authorship. 
For the second and fourth study, I was responsible for the initial founding of the cooperation 
with the involved patient self-help group, ‘Psoriasis Netz’. After several discussions, I created a 
conceptual study design and adapted it according to the reviews by the patient organization and our 
working group. Furthermore, I obtained ethics committee approval and programmed the online 
questionnaire together with Barbara Schuster. After data collection, I was responsible for the data 
preparation, statistical analyses, and writing of the initial manuscript as well as submission of the 
final version that was approved by all co-authors. 
In the third study, my contributions included conceptual design and data analysis. I further wrote 
the first draft of the manuscript, adapted it to all coauthors’ comments, and submitted it. 
For the systematic review (Appendix II), I was responsible for planning the review, defining 
and amending the search terms, defining the inclusion and exclusion criteria, and preparing and 
registering the review protocol. Furthermore, I was responsible for applying the search terms, 
extracting and sorting all data, removing duplicates, and preparing titles, abstracts, and full papers 
for screening and evaluation. I conducted the screening of all abstracts, titles, and full publications. 
I systematically reviewed all publications and evaluated them according to the respective guidelines 
that I defined in the study protocol. I compared them with those of Dr. Linda Tizek and created the 
first draft of the final publication, which I amended according to all comments of the co-authors.   
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Abstract: With the World Health Organization (WHO) demanding further investigation of the social
impairment and psychosocial burden of psoriasis, a first study identified a high prevalence of Internet
addiction. The aim of this study was to assess social impairment and estimate the occurrence of
Internet addiction along with depression, cigarette smoking, and alcohol dependency in individuals
with psoriasis recruited online in a people-centered care approach. A cross-sectional online survey
was carried out across Germany between March 2019 and June 2019. The questionnaire contained
information on social impairment, smoking habits, as well as validated questionnaires on Internet
addiction, depression, and alcohol dependency. Overall, 460 individuals (62.4% female; mean age:
45.9 ± 13.7 years) with psoriasis were included. Of those, 406 (88.3%) stated to be at least rarely
socially impaired. The positive screening rate for Internet addiction was 8.5%. Furthermore, 40.0%
had positive screenings for depression, 17.1% for alcohol dependency, and 32.6% for daily smoking.
Positive screenings for Internet addiction and alcohol dependency were substantially more frequent
in individuals with psoriasis than in the German general population. In order to meet the demands
of the WHO, Internet addiction could be considered as a potential comorbidity in psoriasis and a
focus on people-centered care is advisable for further research.
Keywords: psoriasis; Internet addiction; people-centered care; social impairment; stigmatization
1. Introduction
Internet addiction is a phenomenon first appearing at the turn of the millennium that has since
then begun to rise immensely in importance [1]. It was classified as the most potent problem within
the revised Diagnostic and Statistical Manual of Mental Disorders (DSM) in 2013 [2]. In Germany,
prevalence estimations range from 1.0% in the general population up to 3.2% in the subgroup of
adolescents [3,4]. With regard to skin diseases, a recent study found that pathological Internet use and
Internet addiction were substantially more frequent among a sample of 502 patients with psoriasis
(3.8%) than in the general population (1.0%) [3,5].
Psoriasis is a chronic inflammatory skin disease affecting 1.2–3% of individuals in Germany [6–8].
Patients often have an impaired quality of life and reduced happiness [8,9]. Individuals with psoriasis
J. Clin. Med. 2020, 9, 1818; doi:10.3390/jcm9061818 www.mdpi.com/journal/jcm
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tend to avoid or reduce physical activities and often withdraw themselves from social activities [10,11]
and intimate contact [12,13]. These social impairments are broadly individual for each patient and
associated with various comorbidities [14]. Patients often suffer from a psychosocial burden due
to stigmatization [15,16] as well as from comorbidities such as depression and addictions [17,18].
Subsequently, the World Health Organization (WHO) emphasized the importance of recognizing
the stigmatization in psoriasis and its potential consequences for burden of disease and mental
comorbidities [19]. While reviews indicate more frequent alcohol dependency and cigarette smoking in
psoriasis patients [20,21], evidence on compulsive Internet use and Internet addiction remains limited
to one study [5].
If treated appropriately, patients with psoriasis can benefit from highly effective therapies.
Individuals treated effectively tend to have not only less severe skin lesions but also reduced depressive
symptoms and social impairment [22,23]. The reduction of comorbidities and the promotion of mental
health of individuals with psoriasis are essential according to the WHO [19]. However, not all patients
receive therapies as recommended by guidelines [24,25], and, since not all affected individuals seek
medical care, many affected individuals are not considered as psoriasis patients [26]. Hence, the WHO
demands to focus on people-centered instead of patient-centered health care [27,28]. Despite this,
most research still focuses on registries including mainly, moderately, and severely affected individuals
and typical patient settings such as dermatological practices and clinics. To reach individuals outside
of conventional settings, online approaches can be beneficial [13,29] as many individuals, regardless of
contact to a physician, search for health-related information online [30–33].
The aim of this study was therefore to assess social impairment and to estimate the occurrence of
Internet addiction along with depression, smoking, and alcohol dependency among individuals with
psoriasis using a people-centered online approach.
2. Experimental Section
2.1. Study Design and Recruitment
This cross-sectional study was carried out as an online survey among individuals with psoriasis
in Germany from March to June 2019. The online questionnaire was distributed via an online self-help
platform “Psoriasis-Netz”, a patient online platform “Farbenhaut” as well as a national campaign
of the “Association of the German Dermatologists” (BVDD). The project was most promoted by
“Psoriasis-Netz” on their website together with current information for individuals interested in
psoriasis. Its monthly e-mail newsletter was sent to 2296 registered individuals across Germany.
“Farbenhaut” and the BVDD shared the questionnaire on their social media channels one month before
completion of recruitment for the study.
Only individuals who stated having psoriasis diagnosed by a physician were included in the
analyses. Additional exclusion criteria were the presence of implausible data or more than 20%
of missing values. Electronic informed consent from each participant was acquired prior to study
inclusion. All study procedures were in accordance with the Declaration of Helsinki and were reviewed
as well as approved by the local ethics committee of the Technical University of Munich (reference
25/19 S).
2.2. Questionnaire
The study questionnaire was developed in collaboration with “Psoriasis-Netz”. One dermatologist,
two epidemiologists, and two members of “Psoriasis-Netz” were involved in the process. Questions
were only added if they were accepted unanimously. The questionnaire was pre-tested by three
researchers and three individuals affected by psoriasis and adapted according to their comments.
Participants answered questions on sociodemographic variables and their medical history,
including age, gender, disease severity in general and at time of participation (self-classification as
“mild”, “moderate”, or “severe”, respectively) as well as disease duration and current utilization of
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medical care. Due to the nature of the chosen online approach, standardized reflection of disease
severity using physician-based Psoriasis Area and Severity Index (PASI) or body surface affected (BSA)
was not possible. In order to keep the questionnaire concise, social impairment was assessed with a
one-question item asking “Does your psoriasis prevent you from pursuing certain leisure activities?”,
which could be answered on a five-point Likert scale ranging from “never” to “always”. Participants
who stated that their psoriasis prevents them from taking part in certain leisure activities were asked
for the main restrictions using free-text comments. After revising the questionnaire, examples for
possible answers were added (“e.g., swimming, sauna, sunbathing, . . . ”).
Internet addiction was assessed using the Compulsive Internet Using Scale (CIUS; Cronbach’s
α = 0.93) [34,35]. The questionnaire comprises 14 questions, which are to be answered on a five-point
Likert-scale ranging from “never = 0” to “very often = 4”. Subsequently, the score ranges from 0 to
56. A cutoff score of 21 was used to estimate the prevalence of Internet addiction [5,35]. Additionally,
participants were asked to state the days per week and hours per day spent online in their leisure time.
Depressive behavior was assessed with the International Classification of Diseases (ICD)-10-based
WHO-Five Well-Being Index (WHO-5, Cronbach’s α = 0.88) [36,37], a widely used, validated
questionnaire comprising five questions on well-being. Answers range from “never” to “always” and
are rated from zero to five, respectively. The resulting sum is multiplied by four, resulting in a score
between 0 and 100. A cutoff value of ≤28 for depression showed a sensitivity of 0.94 and a specificity
of 0.83 and, therefore, was used to determine depression as a study outcome [38].
To screen for alcohol use disorder, the DSM-based CAGE-questionnaire was used [39]. It comprises
questions on “cutting down”, “annoyed by criticism”, “guilt about drinking”, and alcohol as an
“eye-opener” in the morning. Questions are answered with “no” or “yes”. The subsequent score ranges
from zero to four. The instrument showed good test-retest reliability (0.80–0.95) and the cutoff value of
at least two questions answered with “yes” as a positive screening for alcohol use disorder previously
showed a sensitivity of 0.71 and a specificity of 0.90 [40].
Smoking was assessed by one question: “Do you smoke cigarettes?”. Participants who stated that
they “never” or “seldom” smoke were classified as non-smokers. Participants who stated that they
smoke daily, regardless of the stated amount, were considered smokers.
2.3. Statistical Analyses
As the online method of patient recruitment of this people-centered survey was explorative,
study size was determined by the number of individuals recruited during a three-month time
frame. Descriptive data were computed for all participants and stratified by social impairment.
Group differences were calculated using unpaired t-tests or chi-square tests. Prevalence of positive
screenings for Internet addiction along with those for depression, smoking, and alcohol dependency
were determined. Results were stratified by gender, age (by median split; 46 years), and social
impairment. To avoid confounding, possible influencing factors were assessed using univariate
and multiple regression models. All factors that showed a significant association in the univariate
analysis, were entered in the multiple regression model with backward selection. Independent
variables included age, gender, disease duration, utilization of medical care, disease severity at
time of study participation, severity in general, and social impairment. Odds ratios (OR) and
respective 95% confidence intervals (95% CIs) were calculated. To analyze activities avoided due to
psoriasis, free-text answers were categorized using an inductive analyzing procedure. Categories
were descriptively quantified. Additionally, quantities of the 50 most commonly used words were
visualized while excluding nonspecific words such as “I”, “with”, or “do”. IBM SPSS Statistics (Version
25, IBM Corporation, Armonk, NY, USA) was used for all analyses and alpha was set at 0.05.
3. Results
A total of 466 individuals with psoriasis participated in this study. Of these, six were excluded
due to implausible data, resulting in a total of 460 participants being analyzed. The mean age was
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45.9 ± 13.7 years and 62.4% (n = 287) of the participants were female. The mean duration of disease
was 21.0 ± 14.7 years and 22.8% (n = 105) of the participants were currently not in medical care.
About half of the participants stated to have a moderate disease severity both at the time of study
participation (55.0%; n = 253) and in general (56.3%; n = 259). When comparing general and current
disease severity, 32.8% (n = 151) of the participants stated that their psoriasis was better at the time of
study participation, while 13.0% (n = 60) indicated a worse disease severity (Table 1).








or Always (n = 330)
Age (years)
(Mean, SD) 45.9 ± 13.7 46.7 ± 14.1 45.6 ± 13.6 0.426
Age group
<46




238 (51.7%) 68 (52.3%) 170 (51.5%)
Gender; n (%)
Female 287 (62.4%) 86 (66.2%) 201 (60.9%)
0.296
Male 173 (37.6%) 44 (33.8%) 129 (39.1%)
Duration of psoriasis (years)
(Mean, SD) 21.0 ± 14.7 21.9 ± 15.1 20.7 ± 14.6 0.416
Currently in medical care; n (%)
Yes 355 (77.2%) 95 (73.1%) 260 (78.8%)
0.189
No 105 (22.8%) 35 (26.9%) 70 (21.2%)
Severity at the time of study participation; n (%)
Mild 102 (22.2%) 47 (36.2%) 55 (16.7%)
<0.001Moderate 253 (55.0%) 74 (56.9%) 179 (54.2%)
Severe 105 (22.8%) 9 (6.9%) 96 (29.1%)
Severity in general; n (%)
Mild 37 (8.0%) 22 (16.9%) 15 (4.5%)
<0.001Moderate 259 (56.3%) 83 (63.8%) 176 (53.3%)
Severe 164 (35.7%) 25 (19.2%) 139 (42.1%)
Severity at study participation compared to severity in general; n (%)
Worse 60 (13.0%) 12 (9.2%) 48 (14.5%)
0.225Equal 249 (54.1%) 77 (59.2%) 172 (52.1%)
Better 151 (32.8%) 41 (31.5%) 110 (33.3%)
SD = standard deviation.
3.1. Social Impairment
Overall, 330 (71.7%) stated that their psoriasis at least sometimes prevents them from certain
leisure activities. Of these, 124 (27.0%) individuals answered this question with “frequently” and 92
(20.0%) with “always”. Participants indicating that their psoriasis prevents them at least sometimes
from certain leisure activities reported a higher rate of severe disease characteristics at the time of study
participation (29.1% vs. 6.9%; p < 0.001) and in general (42.1% vs. 19.2%; p < 0.001) than participants
who indicated no or rare impairment (Table 1).
Furthermore, 406 (88.3%) participants stated that their psoriasis at least rarely prevents them
from any leisure activity. When asked which leisure activities were impaired with an open question,
394 participants (97.0%) provided 552 answers. After qualitatively categorizing all given answers,
“swimming” (n = 273; 67.2%; e.g., “Swimming in public pools. The chlorine burns the skin.”), “sport”
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(n = 93; 22.9%; e.g., “I can’t go jogging anymore as my knees were destroyed by psoriatic arthritis.”),
and “stigmatization and appearance” (n = 49; 12.1%; e.g., “Whenever I can’t put on anything long
enough to hide my disease in public”) were the three most mentioned categories (Table 2). Furthermore,
many answers indicated a reduction in social contacts. For example, people used expressions such as
“meeting new people” and “any activity among people is unpleasant because the strong itching leads
to scratching and leaving dandruff everywhere”. Many individuals also mentioned abstaining from
activities that could exacerbate their symptoms, such as “drinking/eating/partying—all because of the
fear of worsening condition following the consumption of unhealthy food/alcohol”. Reasons given
widely differ within the individuals and the 50 most commonly used words show a multifaceted sense
of loss and preoccupation with daily life for participants due to psoriasis (Figure 1).
Table 2. Inductive categories of free-text answers on what leisure activities were avoided due to
psoriasis. Quantity, two examples, and respective participant characteristics per category.
Category Count n (%) Example Participant (Gender, Age)
Swimming 273 (67.2%)
“Sauna and swimming pool, but only
because of the expected looks on the
affected areas”
Woman, 32 years




“I can’t go jogging anymore as my knees
were destroyed by psoriatic arthritis”.
Man, 32 years




“Whenever I can’t put on anything long
enough to hide my disease in public”
Woman, 50 years
“Any activity requiring short clothing” Woman, 21 years
Sauna 32 (7.9%)
“Sauna, bathing” Man, 73 years
“Sauna, swimming, nudism” Woman, 57 years
Sunbathing 30 (7.4%)
“Sunbathing at the lake” Man, 57 years




“Going for a walk” Woman, 52 years




“Any activity among people is unpleasant




“Visiting restaurants with friends” Man, 38 years
Other 21 (5.2%)
“Everything you need hands for” Woman, 67 years
“Living” Man, 38 years
3.2. Internet Addiction
Participants reported spending 21.6 ± 12.5 h per week online excluding time at work. About four
out of five participants stated being online for private reasons every day (n = 381; 82.8%). Overall,
8.5% (n = 39) of all participants were screened positive for Internet addiction, with no significant
difference in gender (female: 8.5% vs. male: 8.7%, p = 0.935), age (<46 years: 9.1 vs. ≥46 years: 8.0%,
p = 0.660), and social impairment due to psoriasis (“Never or rarely”: 8.5% vs. “Sometimes, frequently,
or always”: 8.5%, p = 0.997; Figure 2, Table A1).
37
J. Clin. Med. 2020, 9, 1818 6 of 15
Figure 1. The 50 most common words in free-text answers on the question, which leisure activities
were prevented by psoriasis. Words were ranked by frequency. Font size (fs) equals the sweeping break
of the third root of word’s rank (rx) times maximal font size (fsmax) [fs = fsmax*rx
−1/3]. As some words
cannot be translated verbatim and free-text answers were given in German, some words are separated
in two or more or appear as duplicates.
3.3. Depression, Smoking, and Drinking
Depressive tendencies were found in 40.0% (n = 180) of the participants (Figure 1). Social
impairment due to psoriasis (at least “sometimes”) was associated with a higher proportion of positive
screening results for depression (45.8% vs. 25.2%; p < 0.001). Furthermore, 32.6% (n = 150) of all
individuals stated to smoke cigarettes daily, and 17.1% (n = 77) were screened positive for alcohol
addiction. More women reported a daily smoking habit (38.3% vs. 23.1%; p = 0.001; Figure 1),
while more men were screened positive for alcohol addiction (25.9% vs. 11.8%; p < 0.001). Additionally,
younger participants more frequently reported smoking cigarettes daily (41.4% vs. 24.4%; p < 0.001).
These differences remained significant when controlled in a multiple regression model, resulting in
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4. Discussion
This study aimed to characterize social impairment and estimate the occurrence of Internet
addiction along with depression, smoking, and alcohol dependency in individuals with psoriasis
recruited via an online, people-centered care approach. Many participants indicated an impairment
due to their psoriasis, with swimming and sports being the most commonly mentioned fields of daily
life being avoided. Given reasons often focused on stigmatization and pain. Furthermore, a high
positive screening rate for Internet addiction and alcohol dependency was found.
4.1. Social Impairment
Overall, 88.3% of participants indicated that their psoriasis prevents them from leisure activities and
meeting other people. Thereby, individuals with more social impairment reported higher self-perceived
disease severity. This finding is in line with a previous study, which found that individuals with
moderate or severe disease severity engaged approximately 30% less in leisure activities than healthy
controls did; no difference was observed for participants with little or no disease activity [10]. In our
study, we not only found that people avoided specific leisure activities such as swimming and
sports but that they also felt stigmatized. This confirms previous findings that stigmatization of skin
lesions was associated with social impairment [16]. Most of the participants mentioned avoiding
swimming. However, it should be noted that examples for leisure activities such as “Swimming,
sauna, sunbathing, . . . ” were provided as suggestions to give participants ideas for possible answers,
potentially resulting in biased free-text answers. The high number of mentions for swimming, however,
reflect a problem identified decades ago [41]. In 1989, a study on 104 psoriasis patients found that
72% of patients avoided swimming, 60% avoided sunbathing, and 40% avoided sports. Although
sunbathing was also mentioned as an example in this study, it was mentioned less frequently in this
sample, while swimming remains an often avoided activity for affected individuals [41]. The stated
reasons of shame, stigmatization, and physical sensations such as burning and itching are in line with
previous literature [10,41]. The fact that patients still abstain from activities such as swimming because
of possible stigmatization emphasizes the importance of current efforts to reduce stigmatization in
psoriasis [15,16], which follows the call for action outlined by the WHO [19]. Another point that might
be addressed in future research is a possible connection between skin and joint pain as well as itch,
and social impairment. Skin pain is an often prevalent symptom [42] and was also frequently reported
in the free-text answers.
4.2. Internet Addiction
Positive screening rates for Internet addiction exceeded those reported in the literature [3–5,43].
In comparison to a German representative study among adolescents, this study’s results were
considerably higher (8.5% vs. 3.2%) [4]. This is surprising, considering the difference in mean age
(45.9 years vs. 14.9 years) and tendency for Internet addiction to occur in younger individuals and to
decrease with age [3]. Even if we were to consider a higher cutoff value of 28, our detected prevalence
of Internet addiction was higher (3.2%) than the prevalence of 1.0% in another German study among
8132 adolescents and adults (mean age: 39.9 years) [3]. Although a third study also used online
recruitment via Facebook groups, they only detected a prevalence of 1.2% of Internet addiction in
245 regular Internet users [43]. Lastly, the prevalence of positive screening results also outnumbered
the prevalence among 502 psoriasis patients recruited from various dermatological practices and clinics
throughout southern Germany (8.5% vs. 3.6%) [5]. Since our results on Internet addiction exceed all
previous reported numbers, this could imply that by recruiting participants online and via patient
platforms as well as a nationwide physician-lead campaign, we were able to reach a highly vulnerable
subgroup of individuals with psoriasis. As another study by Megna et al. found higher signs of
inflammation in patients with psoriatic arthritis who practice smartphone overuse [44], future studies
should include patient stratification by presence of psoriatic arthritis and differentiation between online
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and smart phone addiction. This is, however, one of the first studies to investigate Internet addiction
in psoriasis and further investigation should follow.
4.3. Depression, Smoking, and Alcohol Dependency
Our detected value for positive screenings for depression is similar to one of the highest prevalence
rates reported by a systematic review on depression in patients with psoriasis (questionnaire-based
prevalence: 13.8–39.2%) [17]. The high rate of depression in our study might be explained by the fact
that a people-centered care approach was used instead of a patient-centered approach. This could
be beneficial in reaching especially vulnerable subgroups of affected individuals. In accordance with
preliminary studies in patients with psoriasis [5,18,20,21] and compared to a representative German
sample, individuals with psoriasis reported a higher prevalence of daily smoking (32.6% vs. 15.1%) [45]
and alcohol dependency (17.1% vs. 3.1%) [45]. The gender distribution for smokers was contrary to
that of the general population in which men are more likely to smoke daily than women [45]. Positive
screenings for alcohol dependency (17.1%) also exceeded values reported in two recent German studies
in patients with psoriasis (8.6–13.5%) [5,18]. Possible explanations might include the anonymous
environment of an online survey, a more vulnerable sample in this study, or both.
4.4. Limitations and Strengths
There are some study limitations. As this was an online survey, the truthfulness of participant
answers cannot be verified and prevalences were estimated using screening tools, not diagnoses.
Additionally, due to the anonymity provided by the online design of this study, social desirability
bias could have been reduced. While this is desirable, it makes comparison with previous studies
in medical settings more difficult. Selection bias must be taken into account when considering the
generalizability of these findings. Mainly individuals receiving information, newsletters, or social
media updates from the multiplier institutions were reached. Individuals who are not engaging with
online content related to psoriasis, who are participating in other organizations, or who do not have
an Internet connection were highly unlikely to participate in our study. However, this might have
also led to an especially vulnerable subgroup of affected individuals, which can be desirable when
evaluating mental and social impairment. Those with a high disease burden might be more likely to
search for further information online and therefore have may have a higher chance of receiving a study
invitation through a multiplier organization. Since a high proportion of participants in this study were
not currently in medical care, this online-based recruitment strategy allowed us to reach a unique
group of individuals, who may not have been considered in traditional clinical trials and registries,
further showing the strengths of online outreach. This can broaden the horizon of dermatological
research and strengthen people-centered care [29].
5. Conclusions
The study implicates that social impairment and Internet addiction are high among individuals
with psoriasis recruited via patient networks in a people-centered care and online approach. Positive
screening results for Internet addiction and the other mental health variables exceeded values found for
the general population. The findings on social impairment and addictions emphasize the importance of
mental burden in psoriasis [19] and, therefore, strengthen evidence on the need for programs to reduce
stigmatization [15,16]. Internet addiction was confirmed as an aspect of mental health that should
be considered in further research on individuals with psoriasis. Ultimately, the results indicate that
inclusion of online self-help platforms and their users in health care research could be a key element in
promoting people-centered and not only patient-centered care.
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Table A2. Associated factors for positive screenings for depression, daily smoking of tobacco as well as
alcohol and Internet addiction. Results as crude and adjusted odds ratios.






Age 0.98 (0.96–1.01) -
Gender (male) 0.97 (0.50–1.91) -
Duration of psoriasis 0.97 (0.95–1.00) 0.97 (0.95–1.00)
Currently in medical care (yes) 0.99 (0.46–2.17) -
Severity at the time of study
participation (mild)
- -
moderate 1.34 (0.56–3.24) -
severe 1.29 (0.46–3.60) -
Severity in general (mild) - -
moderate 0.54 (0.19–1.53) -
severe 0.61 (0.20–1.80) -
Social impairment (never or rarely) 1.00 (0.48–2.08) -
Depression 2
Age 0.99 (0.98–1.01) -
Gender (male) 1.14 (0.77–1.68) -
Duration of psoriasis 0.98 (0.97–1.00) 0.98 (0.97–1.00)
Currently in medical care (yes) 1.32 (0.84–2.09) -
Severity at the time of study
participation (mild)
- -
moderate 1.53 (0.92–2.52) 1.34 (0.80–2.25)
severe 2.77 (1.55–4.94) 2.13 (1.16–3.91)
Severity in general (mild) - -
moderate 1.11 (0.53–2.31) -
severe 2.08 (0.98–4.43) -
Social impairment (never or rarely) 2.51 (1.59–3.96) 2.12 (1.32–3.42)
Daily smoking
Age 0.96 (0.95–0.98) 0.96 (0.95–0.98)
Gender (male) 2.07 (1.35–3.16) 2.13 (1.36–3.34)
Duration of psoriasis 0.98 (0.96–0.99) -
Currently in medical care (yes) 0.96 (0.60–1.52) -
Severity at the time of study
participation (mild)
- -
moderate 1.36 (0.81–2.26) -
severe 1.71 (0.95–3.09) -
Severity in general (mild) - -
moderate 2.97 (1.12–7.89) 3.40 (1.24–9.31)
severe 3.99 (1.48–10.78) 4.58 (1.62–12.96)
Social impairment (never or rarely) 2.02 (1.26–3.23) 1.77 (1.07–2.94)
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Table A2. Cont.






Age 1.01 (0.99–1.03) -
Gender (male) 0.34 (0.23–0.63) 0.34 (0.23–0.63)
Duration of psoriasis 1.01 (1.00–1.03) -
Currently in medical care (yes) 1.08 (0.60–1.94) -
Severity at the time of study
participation (mild)
- -
moderate 1.71 (0.88–3.31) -
severe 1.10 (0.49–2.48) -
Severity in general (mild) - -
moderate 2.76 (0.82–9.37) -
severe 1.86 (0.53–6.57) -
Social impairment (never or rarely) 0.79 (0.46–1.33) -
OR = odds ratio; 95% CI = 95% confidence interval; bold values represent significant results at alpha 0.05. 1 Measured
using the Compulsive Internet Using Scale (CIUS; cutoff: ≥21; range: 0–56). 2 Measured using the WHO-Five
Well-Being Index (WHO-5) questionnaire (cutoff: ≤ 29; range: 0–100). 3 Measured using the CAGE questionnaire
(cutoff: ≥ 2; range: 0–4).
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Psoriasis and chronic urticaria (CU) are chronic skin diseases 27 
mental health. Some studies indicate a high prevalence of Internet addiction and many affected 28 
individuals seem not to utilize health care, but rather search for health-related information online. Aims 29 
of the study were to assess Internet addiction as a potential comorbidity in both diseases as well as 30 
identify differences in health care utilization between individuals with psoriasis and CU as well as.  This 31 
cross-sectional study is based on self-reported data from individuals with psoriasis and CU living 32 
throughout Germany using the framework of an online survey from 12/2018 to 01/2019. Advertisements 33 
on Google and Facebook were used to address Internet users who searched online for information on 34 
psoriasis or CU. The study questionnaire comprised questions on demographics, current contact to 35 
physicians, disease history as well as validated screening tools for well-being and Internet addiction. 36 
Overall, 1,686 participants (74.0% female; 38.5% psoriasis) with a mean age of 36.9 ± 12.9 years were 37 
analyzed. Participants with CU were more likely female (89.2% vs. 49.8%; p<0.001) and not in medical 38 
care compared to participants with psoriasis (60.3% vs. 45.9%; p<0.001). Sixteen percent of the 39 
participants overall were screened positive for Internet addiction. Furthermore, not utilizing medical 40 
care showed a significant association with being screened positive for Internet addiction in participants 41 
with CU (adjusted odds ratio (aOR)= 1.49; 95% confidence interval (CI) 1.10-2.02), but not in those 42 
with psoriasis. The study revealed a high proportion of affected individuals not being in medical care 43 
and a high prevalence of Internet addiction, with individuals with CU not utilizing medical resources 44 
having a higher chance of being screened positive for Internet addiction. This underlines the approach 45 
of people-centered care and highlights its importance for further research. 46 
Keywords: Chronic skin diseases; Dermatology; Internet addiction; Depression; Mental Health; 47 




In Europe, the prevalence of psoriasis ranges between 1.3% and 11.4%, with a reported prevalence of 50 
2.0% in Germany [1,2]. Chronic urticaria (CU) has a point prevalence of 0.5% to 1.0% across Europe 51 
[3]. The psychosocial burden of both diseases is high as individuals often experience stigmatization or 52 
social and sexual avoidance [4,5] as well as suffer from comorbidities including mental diseases [6,7]. 53 
For example, studies demonstrated that psoriasis patients showed an addictive behavior regarding 54 
cigarettes and alcohol [8 10]. First studies indicated that psoriasis is potentially associated with other 55 
addictive behaviors such as Internet addiction [11,12]. As Internet addiction represents a rapidly rising 56 
phenomenon of societies worldwide, the fifth edition of the Diagnostic and Statistical Manual of Mental 57 
Disorders mentioned it as the most potent problem needing further research. Therefore, it is essential to 58 
clarify its presence in people with chronic visible skin diseases, who often withdrawal themselves from 59 
social activities [5, 13, 14]. However, those studies used heterogeneous settings as one study included 60 
patients recruited by dermatologists and the other people recruited via psoriasis self-help groups and 61 
showed a wide variation in the Internet addiction rate. The association between CU and Internet 62 
addiction has not been investigated so far. 63 
64 
[15,16]. However, there are barriers in the use of modern treatments and not every patient receives 65 
therapy according to the respective national guidelines [17, 18]. Furthermore, it is important to 66 
distinguish between patients and affected individuals as some persons do not contact a physician due to 67 
their skin disease [19, 20]. The World Health Organization (WHO) hence demands an improvement of 68 
people-centered care in order to bridge the gap between physicians and affected individuals [21, 22]. 69 
Accordingly, psoriasis should be considered as model disease and according to the WHO other chronic 70 
skin diseases were to be included if possible [21]. 71 
When reaching out for individuals suffering from their disease, but do not consult a doctor, prior research 72 
showed that usage of the Internet might be beneficial [23, 24] as it is a commonly used source for health 73 
information [25]. One study showed that 80% of affected people used the Internet to receive initial or 74 
additional information about their disease [26]. Additionally, online search analysis demonstrated that 75 
the burden of specific diseases is high and anonymous online settings might reduce social desirability 76 
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bias [27]. Reaching out for affected individuals online showed first good results in the field of 77 
dermatology [28]. 78 
The aims of this study were (I) to estimate the prevalence of Internet addiction in people suffering from 79 
psoriasis and CU reached online and (II) to identify differences in health care utilization between 80 
individuals with both diseases.  81 
Methods 82 
Study design and participants 83 
This non-interventional cross-sectional study assessed self-reported data from individuals with psoriasis 84 
and CU living throughout Germany using the framework of an online survey from December 2018 to 85 
January 2019. Recruitment was carried out through online banner advertisement on Facebook and 86 
Google. The banners stated e.g. "Psoriasis Survey - participate now!" or "Urticaria  looking for 87 
participants in a survey," and specifically addressed individuals whose prior search behavior indicated 88 
interest in these diseases and therefore represent a certain sub-population of individuals with the 89 
respective disease. Before starting the survey, participants gave their electronic informed consent. 90 
Inclusion criteria were (I) 18 years and older, (II) self-stated physician diagnosis of psoriasis or CU and 91 
associated symptoms within the last three months, and (III) self-stated ability to complete the German 92 
questionnaire. All these criteria had to be answered before being able to start with the questionnaire. If 93 
one question was neglected, participants were guided to the respective self-help web-pages. To ensure 94 
data quality, participants answering less than 80% of study questionnaire were excluded. Ethical 95 
clearance for all analyses was sought from the Ethics Commission of the Faculty of Medicine of the 96 
Technical University of Munich. 97 
Questionnaire 98 
The study was designed by a consortium of two experienced dermatologists and two epidemiologists 99 
and variables were only added or deleted after consensus. Questions asked for general demographics 100 
(age, gender, relationship status, current employment), current utilization of health care system, disease 101 
history (duration of disease, time span from first symptoms to first diagnoses), and mental health aspects 102 
including a short version of the patient health questionnaire (PHQ-D) [29] as well as the short version 103 




I) have you often been bothered by little interest 106 
[29]107 
positive screening for further investigation towards depression. The CIUS is a screening tool for Internet 108 
addiction and consists of five questions using a five-point Likert scale ranging 109 
It represents a reliable questionnaire he suggested cut-off value 110 
, resulting in a sensitivity of 0.95 and a specificity of 0.87 [30, 31]. 111 
To minimize false positive results and to increase reliability of prevalence estimations of Internet 112 
addiction, the cut-113 
increases to 0.96 [30]. Additionally, time spent online per day for leisure as well as days per week spent 114 
online (both not including activities for work) were inquired and summarized as hours spent online per 115 
week for further analyses. Disease severity was measured asking for participants self-stated affected 116 
body surface area (BSA), which was to be estimated in hands (one hand = 1% of body surface) [32]. A 117 
118 
ur questions being answered using a five-119 
point Likert scale (range 0- -off 120 
[33]. To assure high quality of data and minimize bias due to 121 
missing data, several plausibility checks were implemented before the analysis (e.g. the time since 122 
diagnosis or onset of symptoms could not be higher than the age).  123 
Statistics and data management 124 
Descriptive data were generated. Data were stratified by disease as well as by utilization of medical care. 125 
Linear variables were compared using unpaired t-test and categorical variables were compared using 126 
-squared test. To identify factors associated with compulsive Internet use, a logistic 127 
regression was carried out, yielding the screening with literature recommended CIUS cut-128 
as dependent variables. As independent variables, all reported variables available for psoriasis and CU 129 
were added (age, gender, disease (psoriasis/CU), disease duration, disease duration before consulting a 130 
physician for the first time, utilization of health care system, PHQ-D, relationship status). Furthermore, 131 
two disease specific models were calculated including BSA and UCT, respectively. All crude odds ratios 132 
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(OR) and 95% confidence intervals (CI) were calculated. To visualize multicollinearity, correlations 133 
were calculated and reported using the Spearman's rank correlation coefficient. To minimize it, all 134 
variables were added in a multiple regression model and selected via backward selection. After 135 
elimination, adjusted ORs (aOR) and respective 95% CIs were calculated. IBM SPSS Statistics (Version 136 
25, IBM Corporation, Armonk, NY, USA) was used for all analyses and alpha was set to 0.05. 137 
Results 138 
characteristics and comparison of disease 139 
Overall, 3,222 individuals opened the first page of the survey and 1,686 completed it, resulting in a rate 140 
141 
age was 36.9 ± 12.9 years. More participants with CU took part (ncu=1,037 vs. npso=649) and those had 142 
a higher proportion of females (89.2% vs. 49.8%, p<0.001) as well as a younger mean age (33.4 ± 10.9 143 
years vs. 42.5 ± 13.7 years; p<0.001). Mean UCT was 7.9 ± 3.9, indicating that 79.6% of participants 144 
with CU were uncontrolled. Mean BSA was 6.1 ± 8.0, with a mild disease in 83.6% of participants with 145 
psoriasis. Individuals with psoriasis indicated a longer disease duration (18.1 ± 12.7 years vs. 10.0 ± 9.3 146 
years, p<0.001) and a longer timespan between the first symptoms and consulting a physician (7.0 ± 7.9 147 
-148 
D, which indicates a psychosocial disturbance, and about one in two participants scored two, which 149 
indicates further investigation for the presence of a depressive tendency.  150 
Estimated prevalence of Internet addiction 151 
In the CU group, people not being in medical care had significantly higher CIUS score (5.0 ± 3.8 vs. 4.2 152 
± 3.6; p=0.001) and a higher proportion of positive screenings for compulsive Internet use (cut-153 
than those receiving medical care (29.4% vs 22.6%; p=0.014; Table 2). In the psoriasis group, no 154 
difference was observed (Table 2). Participants not consulting a physician reported a longer time spent 155 
online within a week (21.4 ± 20.2 h/week vs. 19.9 ± 18.8 h/week; p=0.130). 156 
Overall, 16.0% of participants were screened positive for compulsive Internet use (cut-157 
indicating an Internet addiction. The proportion of positive screenings was not significantly higher 158 
among participants not receiving medical care (17.6% vs. 14.2%; p=0.058) and participants with CU 159 
(16.9% vs. 14.6%; p=0.223; Fig. 2).  160 
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Associated factors for Internet addiction 161 
Of all participants, 1,618 (96.0%) had complete datasets and were included in the first logistic regression 162 
model. The chance of having a positive screening for Internet addiction decreased with rising age 163 
(aOR=0.97; 95% CI 0.96-0.98; Table S1). Compared to that, being not in medical care (aOR=1.30; 95% 164 
CI 1.03-1.63), not being in a relationship (aOR=1.32; 95% CI 1.02-1.70), and having higher scores in 165 
the PHQ-D were associated with a positive screening for Internet addiction (aORPHQ-D=1=1.51; 95% CI 166 
1.06-2.14; aORPHQ-D=2=2.35 95% CI 1.78-3.11; Fig. 3). 167 
When stratified by disease, the association of gender vanished in both diseases. The high correlation 168 
coefficient of gender and disease (rs=0.44; p<0.001; Table S2) therefore indicated an effect modifying 169 
nature of gender in this model. Furthermore, the association of medical care and compulsive Internet 170 
use vanished in participants with psoriasis, while the aOR increased in CU (aOR=1.49; 95% CI 1.10-171 
2.02).  172 
Stratification by the utilization of medical care 173 
The proportion of people currently not in medical care was significantly higher among individuals 174 
suffering from CU than psoriasis (60.3% vs. 45.9%; p<0.001; Table 1). In general, participants currently 175 
receiving medical care were younger (35.6 ± 12.5 years vs. 38.5 ± 13.2; p<0.001) and had waited longer 176 
after onset of symptoms until they consulted a physician (6.4 ± 7.7 years vs. 4.8 ± 6.6 years; p<0.001). 177 
They showed a longer disease duration (13.6 ± 11.3 years vs. 12.3 ± 11.5 years; p=0.026) compared to 178 
individuals who reported not receiving medical care. Patients with CU in medical care showed a lower 179 
UCT (6.9 ± 3.9 vs. 8.5 ± 3.8; p<0.001), indicating that they had a less controlled disease. Additionally, 180 
participants with CU not seeking medical care showed an increased CIUS score (5.0 ± 3.8 vs. 4.2 ± 3.6; 181 
p<0.001) and more positive screenings for compulsive Internet use (29.4% vs. 22.6%; p=0.014) 182 
compared to those who were in medical care. Participants with psoriasis showed the same trend, 183 
however it was not significant. Furthermore, PHQ-D was more likely to be higher in participants seeing 184 
a physician for their CU, while no significant difference was identified within participants with psoriasis 185 
(Table 2). 186 
Discussion 187 
The aims of this study were to (I) estimate the prevalence of Internet addiction among people with 188 
psoriasis and CU reached online and (II) to identify differences in health care utilization between both 189 
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diseases. By using online advertisement, a high proportion of individuals who were currently not in 190 
medical care was reached. Positive screening rate for Internet addiction was high and the chance to have 191 
a positive screening was higher in younger participants, in individuals who were currently not seeing a 192 
doctor, and in individuals having depressive tendencies. 193 
Stratification by disease 194 
Although it is reported that females have a slightly higher prevalence for CU than men [3,34], the 195 
proportion of females with reported CU in this study was very high. One possible explanation might be 196 
the higher frequency of young individuals and women searching for health related information online 197 
[33-35]. However, this assumption is not supported by age and gender distribution compared to 198 
individuals with psoriasis participating in the survey. Yet, it remains unclear why these gender 199 
differences were reached and needs future research.  200 
Estimated prevalence of Internet addiction 201 
Reported values of Internet addiction in Germany among the general population range from 1.0 to 5.0%, 202 
depending on age group [38, 39]. In 2014, a large German study including 8,130 individuals reported 203 
an Internet addiction prevalence of 1.0 to 1.5% [40]. Accordingly, the herein found rate for positive 204 
screening of 16.0% appears to be tremendously high. One important reason for these considerable 205 
differences could be that participants showing symptoms of an Internet addiction are more likely to 206 
spend more time online and therefore being reached via an online survey or online advertisements. As 207 
this study online included people reached online, individuals with no access to the Internet were not able 208 
to participate in this study. However, a comparable study reported a prevalence of 1.2% among 249 209 
regular Internet users. The authors also relied on a web-based design using Facebook for recruitment 210 
and the study period lasted less than two months [39]. The study results, however, did not only indicate 211 
a higher rate of Internet addiction in comparison to the general population, but also in comparison with 212 
two previous studies among people with psoriasis. For example, in a study among individuals with 213 
psoriasis reached via online self-help groups the reported prevalence was 8.5% [12] and in a study 214 
among psoriasis patients recruited offline, in clinics and dermatological offices, the prevalence was 3.8% 215 
[11]. Therefore, the way affected individuals are reached seems to be essential for the frequency of 216 
positive screenings for Internet addiction. Although using an online setting to investigate Internet 217 
addiction might overestimate the actual problem, this might not be the only reason for these large 218 
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differences, but also promotes the use of online tools and advertisements to reach a potentially 219 
vulnerable sub-sample of people with chronic skin diseases. While there is no evidence on rate of 220 
Internet addiction among people with CU in the literature so far, a previous study indicated compulsive 221 
tendencies in patients with urticaria [41]. This is an important finding and needs further investigation.   222 
Associated factors for Internet addiction 223 
Like in the literature, Internet addiction was associated with younger age [39] and showed no gender 224 
differences [40]. Additionally, the study could confirm depressive tendency being positively associated 225 
with Internet addiction [42, 43]. As this is the first study which investigate the issue in chronic skin 226 
disease including individuals with and without contact to a physician, it is highly interesting that affected 227 
individuals who were currently not in medical care had a higher chance of a positive screening for 228 
Internet addiction. When stratified by disease, this difference vanished in participants with psoriasis, 229 
while it increased in participants with CU. In combination with diminishing effects of relationship status 230 
due to stratification, this indicated the role of disease as possible confounder. Therefore, the exact nature 231 
of this association and potential causality should be investigated in future studies. Further studies are 232 
needed and registry data or data including a suitable control group might be highly beneficial. 233 
Stratification by the utilization of medical care 234 
The study indicated that people being not in medical care had a milder disease form which might be due 235 
to the fact that their disease might be already controlled compared to those who are receiving medical 236 
care. The mean UCT value of 8.5 was remarkably below the score indicating a controlled disease (=12). 237 
Indeed, three out of four people not being in medical care indicated an uncontrolled CU. However, 238 
controlling the disease was reported to be a major aim in CU [34, 44, 45] and the proportions of poorly 239 
controlled individuals was higher in this study than previously reported in the literature (79.6% vs. 240 
36.5%) [34]. A possible explanation might be that individuals with a less controlled CU are more likely 241 
242 
advertisements might mainly have reached these individuals. By all means, modern and effective 243 
therapies do not have an added value if people do not receive them [46].  244 
The longer disease duration of participants of both groups not being in medical care underlines the 245 
necessity of medical advice and care. Furthermore, it could indicate a drop out of medical care as a result 246 
of long disease duration and frustrated expectations in sufficient and promising treatments. This would 247 
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be in accordance with previous findings [47].  248 
Participants with CU receiving medical care reported depressive tendencies more often. While about 249 
one in three participants not seeing a physician showed no signs of depressive tendency, in the sub-250 
group of participants currently under medical care only one in five did. An explanation for this difference 251 
might be the high proportion of poorly controlled CU in the first group, which is reported to be highly 252 
burdening [48]. Furthermore, physicians, especially dermatologists could be sensitized to this issue.   253 
Limitations and strengths 254 
There are some study limitations. First of all, study participants stated self-reported that they suffer 255 
either from psoriasis or CU and study fraud cannot be excluded. Measures to minimize the chance of 256 
including bots and frau257 
plausibility checks) [49]. However, due to the anonymous study design measures including geolocation 258 
or the IP-address of participants were not feasible, even though they were shown to be highly effective 259 
[49, 50]. Furthermore, all answers were self-stated and so, for example, BSA in participants with 260 
psoriasis might differ from actual BSA measured by a dermatologist. Another limitation is that no exact 261 
response rate can be stated. It is known, that 50.8% of individuals who reacted via the advertisement 262 
took part in the survey, however it is unclear for how many Internet users the survey was displayed. 263 
Additionally, there was a large potential of selection bias. The proportion of female participants was 264 
extremely high, although there are no considerable differences in the prevalence of psoriasis and CU 265 
among females and males. Furthermore, only individuals with Internet access and only those actively 266 
searching for psoriasis or CU related topics have been reached. This substantially reduces the chance of 267 
achieving a representative sample of all individuals with psoriasis and CU, respectively. However, this 268 
might also be a major strength of this study: participants might not be representative for all individuals 269 
with psoriasis or CU, but it highlights the need to reach affected individuals. Those individuals suffering 270 
from the symptoms of their disease might be more likely to search online and subsequently react to the 271 
advertised posts. Furthermore, more than half of all participants were not in medical care and therefore 272 
are highly unlikely to be reached throughout conservative epidemiological studies and registries 273 
focusing on patients instead of all affected people. Consequently, this approach might contribute to 274 
broaden the horizon of medical research and could be promising to address individuals with high disease 275 
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burden and no contact to a physician, underlining its importance mentioned in a prior review [28]. 276 
Conclusion 277 
In conclusion, many individuals with psoriasis and CU were reached through this online survey, of those 278 
a large proportion reported to receive no medical care. The study revealed a high occurrence of Internet 279 
addiction in participants, demonstrating that individuals with CU not being in medical care have a higher 280 
chance of being screened positive. Accordingly, these findings underline the importance of a people-281 
centered approach and the potential of online settings for dermatological research [28]. Additionally, it 282 
reveals that online surveys might be a valuable tool if vulnerable groups have to be included in future 283 
research. Future studies could include an age and gender adjusted control group as well as health 284 
insurance data to clarify whether the risk of Internet addiction is increased among patients with psoriasis 285 
or CU. They should focus on identifying ways to reach individuals not seeking medical care despite 286 
suffering from these diseases.  287 
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Legends for Figures 439 
Figure 1: Flow chart of participant recruitment and exclusions in both study arms. 440 
Figure 2: Prevalence of positive screenings for Internet addiction (results of the short form of the Compulsive 441 
Internet Using Scale; cut-442 
CIUS=short form of the Compulsive Internet Using Scale. 443 
Figure 3: Results of the multiple regression that showed associated factors with the positive screening on 444 
compulsive Internet use. A) including all participants; B) Stratified by disease. aOR = adjusted odds ratio; Age in 445 











Participants stratified by disease 




Age [Mean ± SD]  36.9±12.9 42.5±13.7 33.4±10.9 <0.001 
Gender [n (%)] 
female 1248 (74.0) 323 (49.8) 925 (89.2) 
<0.001 
male 438 (26.0) 326 (50.2) 112 (10.8) 
BSA  
[Mean ± SD] NA 6.1±8.0 NA 
NA 
[n (%)] 
mild NA 539 (83.6) NA 
moderate / severe NA 106 (16.4) NA 
missing NA 4 NA 
UCT  
[Mean ± SD] NA NA 7.9±3.9 
[n (%)] 
controlled NA NA 212 (20.4) 
Poorly controlled NA NA 825 (79.6) 
Disease 
duration   
[Mean ± SD; years] 13.0±11.4 18.1±12.7 10.0±9.3 <0.001 
[n (%)] 
 871 (53.8) 216 (35.3) 655 (65.1) 
<0.001 
> 10 years 747 (46.2) 396 (64.7) 351 (34.9) 
Disease duration before 
consulting a physician [Mean ± 
SD; years] 
 5.7±7.3 3.6±5.4 7.0±7.9 <0.001 
Currently in medical care [n (%)] 
Yes 763 (45.3) 351 (54.1) 412 (39.7) 
<0.001 
No 923 (54.7) 298 (45.9) 625 (60.3) 
Profession [n (%)] 
full-time 812 (48.2) 348 (53.6) 464 (44.7) 
<0.001 
part-time 322 (19.1) 91 (14.0) 231 (22.3) 
other 472 (28.0) 174 (26.8) 298 (28.7) 
unemployed 80 (4.7) 36 (5.5) 44 (4.2) 
PHQ-D-Score [n (%)] 
0 503 (29.8) 213 (32.8) 290 (28.0) 
0.087 1 333 (19.8) 118 (18.2) 215 (20.7) 
2 850 (50.4) 318 (49.0) 532 (51.3) 
In a relationship [n (%)] 
Yes 1,273 (75.5) 485 (74.7) 788 (76.0) 
0.559 
No 413 (24.5) 164 (25.3) 249 (24.0) 
CIUS Score [Mean ± SD]  4.6±3.6 4.4±3.5 4.7±3.7 0.157 
Compulsive Internet use [n (%)] 
Yes 431 (25.6) 154 (23.7) 277 (26.7) 
0.172 
No 1255 (74.4) 495 (76.3) 760 (73.3) 
Differences were compared using unpaired t-test and Chi square test. SD=Standard deviation; NA=Not applicable; 449 
BSA=Body surface area (self-stated); UCT=Urticaria Control Test; PHQ-D= short version of the patient health 450 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Tables 455 
Table S1: Associated factors with the occurrence of Internet addiction in individual logistic regressions and in a multiple 456 




Crude OR  
(95% CI) 
Adjusted OR  
(95% CI) 
Internet addiction 
(CIUS cut-  
 
n = 1618 
 
Age [years] 0.97 (0.96-0.98) 0.97 (0.96-0.98) 
Gender (female) 1.05 (0.82-1.35) - 
Disease (psoriasis) 1.17 (0.93-1.47) - 
Disease duration [years] 0.99 (0.99-1.00) - 
Disease before consulting a 
physician [years] 
1.01 (0.99-1.02) - 
In medical care (yes) 1.34 (1.07-1.67) 1.30 (1.03-1.63) 
PHQ-D (0) 
1 1.57 (1.11-2.22) 1.51 (1.06-2.14) 
2 2.34 (1.78-3.09) 2.35 (1.78-3.11) 





n = 609 
 
Age [years] 0.98 (0.97-0.99) 0.98 (0.97-0.99) 
Gender (female) 1.06 (0.74-1.52) - 
BSA 1.01 (0.99-1.04) - 
Disease duration [years] 1.00 (0.98-1.01) - 
Disease before consulting a 
physician [years] 
1.02 (0.99-1.06) - 
In medical care (yes) 1.16 (0.81-1.66) - 
PHQ-D (0) 
1 1.86 (1.07-3.24) 1.82 (1.03-3.23) 
2 2.19 (1.40-3.41) 2.13 (1.35-3.38) 
In a relationship (yes) 1.30 (0.87-1.95) - 
Internet addiction 
(CIUS cut-  
 
n = 1,006 
Age [years] 0.95 (0.94-0.97) 0.95 (0.94-0.97) 
Gender (female) 1.34 (0.88-2.05) - 
UCT-score 0.98 (0.94-1.01) - 
Disease duration [years] 1.00 (0.98-1.01) - 
Disease before consulting a 
physician [years] 
1.00 (0.98-1.02) - 
In medical care (yes) 1.43 (1.07-1.91) 1.49 (1.10-2.02) 
PHQ-D (0) 
1 1.42 (0.91-2.20) 1.39 (0.88-2.20) 
2 2.41 (1.69-3.44) 2.63 (1.82-3.80) 
In a relationship (yes) 1.49 (1.10-2.04) - 
OR = odds ratio; CIUS = short version of the Compulsive Internet Using Scale; PHQ-D = short version of the 458 
patient health questionnaire; CU = chronic urticaria; BSA=Body surface area (self-stated); UCT=Urticaria Control 459 
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SIGNIFICANCE
Patients with genital psoriasis have a poorer quality of life 
and more sexual distress. Therefore, we conducted an on-
line-based nationwide survey across Germany addressing 
persons living with psoriasis. Overall, we had 344 partici-
pants. Of these, 198 (57.6%) stated to have genital pso-
riasis and 83 (24.1%) did not see a doctor at the moment. 
Most prevalent reasons to avoid sexual activities were 
‘shame,’ ‘pain,’ and ‘fear of rejection.’ Avoidance of sexual 
contact is high in individuals reached via this online-survey 
and needs to be further addressed. Furthermore, the ap-
proach of reaching out for persons, not patients could re-
present a great asset for future health care.
Patients with genital psoriasis show poorer outcomes 
regarding quality of life and sexual distress than those 
without. This study aimed to assess the occurrence of 
genital psoriasis and to determine factors associated 
with the avoidance of sexual activities due to psoriasis 
in a non-clinical setting. A cross-sectional, person-cen-
tered, and online-based nationwide survey was con-
ducted in Germany between March and June 2019. A 
multiple logistic regression model was used to analyze 
the data. Furthermore, free-text answers were pro-
vided. Overall, 344 individuals with psoriasis partici-
pated. Of these, 198 (57.6%) reported having genital 
psoriasis and 261 (75.9%) currently received medical 
care. Duration of psoriasis, subjective overall severity, 
and pain during sex were associated with the avoidan-
ce of sexual activities. Most prevalent rea sons to avoid 
sexual activities were ‘shame,’ ‘pain,’ and ‘fear of re-
jection.’ Sexual distress was high in this sample and 
a person-centered care approach needs to be further 
promoted.
Key words: genital psoriasis; sexual behavior; sexual health; 
avoidance; people-centered; person-centered.
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Psoriasis affects approximately 2% of individuals in Europe, with an enormous psychosocial component 
among affected individuals and their families (1–4). Pso-
riasis can affect all parts of the body, including the genital 
area (3). The reported exam-based point prevalence of 
genital psoriasis ranges from 12 to 42% in patients with 
between the studies (5). With growing knowledge about 
psoriasis (6, 7), its treatment is constantly progressing, 
and availability of highly effective treatment is increasing 
(8–10). When appropriately recognized, genital psoriasis 
Psoriasis is associated with many comorbidities, such 
as depression and anxiety (1, 13, 14). Additionally, men-
on sexual health (15). According to the World Health 
Organization (WHO), the reduction of mental health 
comorbidities is important to improve people’s overall 
health (16, 17). Particularly, psoriasis patients whose ge-
nital area is affected showed an increased mental burden, 
distress when compared to psoriasis patients without 
genital involvement (18–20). Although it is important 
that physicians assess the occurrence of genital psoriasis 
to prevent possible impairment of patients’ sexual heath 
(19,20), genital involvement often remains unnoticed 
(20). Another problem is that not all affected individu-
als seek medical healthcare from a physician (21–24). 
Therefore, the WHO encourages the concept of people-
centered care, not patient-centered care, in order to broa-
den the scope of research and promote public health (21, 
25). Additionally, the link between genital psoriasis and 
the avoidance of sexual activities has not been addressed 
The aims of this study were (i) to assess the occur-
rence of genital psoriasis in a non-clinical setting, and 
(ii) to determine factors associated with the avoidance 
of sexual activities due to psoriasis from the perspective 
of affected individuals. 
MATERIALS AND METHODS
Study design
This cross-sectional study was designed as an online survey and 
carried out among individuals with psoriasis across Germany 
between March 2019 and June 2019. The survey was promoted 
on different channels (social media channels, webpages, and 
newsletters) by patient organizations, including “Psoriasis-Netz,” 
“Farbenhaut,” and a campaign of the Association of the German 
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Maximilian Christian SCHIELEIN1,2, Linda TIZEK1,2, Barbara SCHUSTER1,2, Stefanie ZIEHFREUND1, Tilo BIEDERMANN1 and 
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and timespan of recruitment by each organization. Most people 
participated via “Psoriasis-Netz,” which is a patient organization 
website providing relevant and up-to-date information for indi-
viduals affected by psoriasis or interested in psoriasis treatment. 
The survey was shared within their monthly e-mail newsletter, 
which reaches up to 2,296 registered individuals across Germany. 
webpage and social media accounts. “Farbenhaut” and the BVDD 
one month before the survey was closed. Inclusion criteria were 
self-reported psoriasis diagnosed by a physician (all sub-types of 
psoriasis) and age at time of participation of 18 years or older. The 
-
tionnaire. Prior to participation, all individuals provided electronic 
informed consent. Only individuals reported having a diagnosis of 
psoriasis made by a physician were included in the analysis. Entries 
were directed to a page with web links that provided information 
about psoriasis, its comorbidities, and treatment options, as well 
as links to several local self-help groups across Germany. The 
study was approved by the local ethical committee of the Medical 
Faculty of Technical University of Munich (Reference: 25/19 S).
Questionnaire
of Munich. Detailed information can be found in Appendix S11. 
Statistical analysis
Data were collected using SoSci survey online tool (Version 
3.2.02-i) (28). Descriptive statistics were provided for all vari-
ables. Differences between participants with or without genital 
psoriasis were analyzed using an unpaired t-test for continuous 
-
contact due to their psoriasis, univariate and multivariate logistic 
regression analyses were performed. First, the role of participant 
characteristics (age, sex, duration of psoriasis, severity of pso-
characteristics of participants’ sexual life (occurrence of genital 
psoriasis, relationship status, pain during sexual activities due to 
psoriasis) for the tendency to avoid sexual contact were tested. 
regression were included in the multivariate backward selection 
calculated for both models. To avoid multicollinearity, correlations 
of all variables were calculated using Spearman correlations (rs) 
before inclusion in the multivariate model. Data management and 
analyses were performed using IBM SPSS Statistics 25 (IBM 
p-
value) was set at 0.05. 
Free text answers
To analyze, paraphrase, and categorize free-text answers to the 
procedure using MAXQDA Analytics Pro software, version 18.0.0 




A total of 351 individuals with psoriasis completed the 
survey and 344 were included in the presented data (Fig. 
S11). The response rate of the institution including the 
most participants (“Psoriasis-Netz”) was 13.9%, when 
considering their e-mail newsletter. The participants’ 
mean age was 44.6 ± 13.2 years, and 59.3% of participants 
were women (Table I). Overall, 261 of 344 (75.9%) sta-
ted that they currently saw a physician due to psoriasis. 
Genital psoriasis and impact on sexual activities
More than half of the participants (n = 198; 57.6%) stated 
that their genital area was affected by psoriasis. Genital 
psoriasis was more prevalent in men than in women 
(65.0% vs. 52.5%; p = 0.021), and individuals with 
genital psoriasis were less likely to report subjectively 
mild psoriasis at the time point of participation (15.2% 
vs. 28.1%; p = 0.007). Overall, individuals reported an 
increased avoidance of sexual activities after onset of 
difference was observed between participants who later 
were or were not affected by genital psoriasis prior to 
psoriasis onset (31.8% vs. 26.0%; p = 0.238); however, 
more individuals with genital involvement tended to 
avoid sexual activities after psoriasis onset (74.2% vs. 
52.7%; p < 0.001; Table I). The proportion of indivi-
applicable decreased after onset of psoriasis (23.8% vs. 
9.3%). Of those participants avoiding sexual activities 
due to psoriasis, those with genital involvement more 
from non-avoiding to avoiding (40.0% vs. 31.2%; Fig. 
1). Of those reporting not to avoid sex due to psoriasis, 
most did not avoid sexual activities prior to onset either, 
regardless of the genital involvement (78.8–80.6%; Fig. 
1). Individuals with genital psoriasis stated more often 
to “always” avoid sexual contact (13.6% vs. 5.5%, 
p = 0.001). Furthermore, participants with genital psoria-
sex life (73.2% vs. 57.5%; p < 0.001). More than half 
of all participants (n = 184; 53.3%) stated that psoriasis 
-
rences were observed between the sub-groups regarding 
genital psoriasis.
Overall, 201 participants (71.8%) reported to avoid 
sexual contact at least sometimes due to their psoriasis. 
higher age and longer duration of disease (rs 0.39; 
p < 0.001) as well as between genital involvement and 
pain during sex (rs 0.33; p < 0.001; Table S11). Univariate 
associated with avoidance. For example, people with a 
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Variables Overall (n = 344)
Genital area affected by psoriasis
p-valueYes (n = 198; 57.6%) No (n = 146; 42.4%)
Age, mean ± SD 44.6 ± 13.2 43.6 ± 13.1 45.9 ± 13.2 0.171
Sex, n (%)
Women 204 (59.3) 107 (52.5) 97 (47.5) 0.021*
Men 140 (40.7) 91 (65.0) 49 (35.0)
Do you receive medical care due to psoriasis? n (%)
Yes 261 (75.9) 153 (77.3) 108 (74.0) 0.480
No 83 (24.1) 45 (22.7) 38 (26.0)
Duration of psoriasis, mean ± SD 20.3 ± 14.2 19.4 ± 13.1 21.6 ± 15.4 0.159
Age of mean onset of psoriasis, mean ± SD 24.2 ± 14.3 24.2 ± 13.1 24.3 ± 15.8 0.985
Subjective overall severity of psoriasis, n (%) 
Mild 28 (8.1) 13 (6.6) 15 (10.3) 0.299
Moderate 193 (56.1) 109 (55.1) 84 (57.5)
Severe 123 (35.8) 76 (38.4) 47 (32.2)
Subjective severity of psoriasis at the time point of participation, n (%)
Mild 71 (20.6) 30 (15.2) 41 (28.1) 0.007*
Moderate 193 (56.1) 123 (62.1) 70 (47.9)
Severe 80 (23.3) 45 (22.7) 35 (24.0)
Are you in a relationship? n (%)
Yes 235 (68.3) 140 (70.7) 95 (65.1) 0.267
No 109 (31.7) 58 (29.3) 51 (34.9)
Do you suffer from pain during sexual activities due to your psoriasis? n (%)
Yes 154 (44.8) 116 (58.6) 38 (26.0) <0.001*
No 135 (39.2) 59 (29.8) 76 (52.1)
Not applicable 54 (15.7) 22 (11.1) 32 (21.9)
Missing 1 (0.3) 1 (0.5%) –
Did you avoid sexual contact prior to onset of psoriasis? n (%)
Yes 101 (29.4) 63 (31.8) 38 (26.0) 0.238
No 159 (46.2) 92 (46.5) 67 (45.9)
Not applicable 82 (23.8) 41 (20.7) 41 (28.1)
Missing 2 (0.6) 2 (1.0) –
Do you avoid sexual contact due to your psoriasis? n (%)
Yes 224 (65.1 147 (74.2) 77 (52.7) <0.001*
No 88 (25.6%) 36 (18.2) 52 (35.6)
Not applicable 32 (9.3%) 15 (7.6) 17 (11.6)
Missing – – –
n (%)
Yes 229 (66.6) 154 (73.2) 84 (57.5) <0.001*
No 112 (32.6) 52 (26.3) 60 (41.1)
Missing 3 (0.9) 1 (0.5) 2 (1.4)
n (%)
Yes 184 (53.3) 107 (54.0) 77 (52.7) 0.811
No 160 (46.4) 91 (46.0) 69 (47.3)
Missing – – –
SD: standard deviation.
Fig. 1. Proportion of individuals avoiding sexual 
activities before and after onset of psoriasis. 
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1.07–3.20) were more likely to avoid sexual contact due 
to psoriasis. After using backward selection in the mul-
tiple logistic regression model, the remaining factors for 
the avoidance of sexual activities due to psoriasis were 
-
pain during sexual activities due to psoriasis (OR 3.41, 
Table II).
Reasons to avoid sexual activities
Overall, approximately half of the participants stating 
to avoid sexual activities gave a reason for doing so 
-
categories. Double categorization was possible in cases 
such as “Dandruff that falls out of the hair, itchiness.” 
Most prevalent categories were ‘Shame’ (n = 54; e.g., 
“Sometimes I don’t feel comfortable in my skin” or “I 
feel ashamed”); ‘Pain’ (n = 35; e.g., “The painful open 
wounds around the genital area” or in many cases just 
“Pain”); ‘Fear of rejection’ (n = 20; e.g., “I believe that 
my psoriasis is repulsive for others” or “I don’t want 
to see other people’s disgusted/deterred facial expres-
sions”); and ‘Genital psoriasis’ (n = 14; e.g., “My penis 
really hurts when my skin cracks from the psoriasis,” 
and “Ashamed due to severe attack of the genital area”, 
Fig. 2a). Furthermore, statements were made on stigma-
tization during youth (e.g., “I believe that the exclusion 
due to psoriasis in my childhood still negatively impacts 
my body image or at least negatively impacted it for a 
while.”) and the need to explain the disease repeatedly 
(e.g., “The need to constantly explain my disease”). Most 
prevalent words used were “psoriasis” (n = 28), “shame” 
(n = 25), and “pain” (n = 24; Fig. 2b).
DISCUSSION
The aims of the study were to assess the occurrence of 
genital psoriasis in a non-clinic setting and to determine 
due to psoriasis from the perspective of affected in-
dividuals. Of 344 participants with psoriasis, 198 had 
genital involvement. Individuals with genital psoriasis 
activities due to their psoriasis than those without ge-
nital involvement. Furthermore, a shorter duration of 
psoriasis, an overall more severe psoriasis, and pain 
during sex were associated with the avoidance of sexual 
activities, which further led to sexual distress. 
Additional reasons included shame, pain, and 
the fear of rejection.
The occurrence of genital involvement was 
57.6%, which is considerably higher than 
the rates reported previously (between 7% 
and 42%) (29–32). The high prevalence rate 
underlines the recommendation by Meeuwis 
et al. (19) that physicians should check for 
genital involvement in patients with psoriasis 
and pay attention to the impact of psoriasis 
on psychosocial aspects and sexual health. On 
one hand, prior studies conducted in medical 
settings may have underestimated the preva-
Table II. Factors associated with avoidance of sexual contact due to psoriasis in 312 study participants
Independent variable (reference category)
Univariate logistic regression Multiple logistic regressiona
OR (95% CI) p-value aOR (95% CI) p-value
Age (years) 0.98 (0.96, 1.00) 0.059
Sex (male) 0.82 (0.50, 1.35) 0.437
Duration of psoriasis (years) 0.98 (0.96, 0.99) 0.030 0.97 (0.95, 0.99) 0.012
subjective overall severity (mild) 1 < 0.001 1 0.010
Moderate 3.52 (1.53, 8.12) 0.003 3.49 (1.35, 9.04) 0.001
Severe 6.08 (2.48, 14.93) < 0.001 5.35 (1.93, 14.79) < 0.001
Severity at time of study participation (mild) 1 0.144
Moderate 1.53 (0.85, 2.79) 0.160
Severe 2.07 (0.99, 4.35) 0.054
Receiving medical care (yes) 1.85 (1.07, 3.20) 0.028
Genital area affected by psoriasis (no) 2.76 (1.66, 4.58) < 0.001
In a relationship (yes) 1.75 (0.99, 3.09) 0.055
Pain during sexual activities due to psoriasis (no) 4.18 (2.38, 7.34) < 0.001 3.41 (1.90, 6.13) < 0.001
an 
Fig. 2. Free text answers of affected individuals regarding the question for 
personal reasons for avoidance of sexual contact due to psoriasis. Font size in 
proportion to frequency of entries (actual font size equals square root of proportion times 
largest font size). (a) categories of reasons individuals mentioned as a reason to avoid 
sexual activities due to their psoriasis. Maximal mentioning: Shame, n = 54. (b) quantitative 
visualization of 20 most common words individuals mentioned during giving a reason 
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lence, as they did not include individuals who are not 
seeing a physician for the treatment of their psoriasis, 
which might be due to shame caused by genital invol-
vement. Alternatively, the high prevalence in this study 
could stem from selection bias, as affected individuals 
might be more interested in taking part in a study about 
genital psoriasis. Nonetheless, in line with previous 
studies that have shown a prevalence of up to 42%, the 
prevalence in the present study may also indicate a vul-
organizations and non-healthcare professional settings. 
Additionally, the present results are in line with previous 
studies that report that men are more likely to develop 
important for dermatologists, as therapy can be optimized 
if knowledge of involvement of this hard-to-treat area is 
present. Therefore, communication with the patient about 
this topic is essential and barriers need to be minimized. 
of physician-patient relationships or patient information 
When considering the avoidance of sex before and 
after psoriasis onset, a clear change in participants’ be-
havior occurred (Fig. 1). Interestingly, the opinion that 
applicable decreased after the onset of psoriasis. The 
reason for this might include individuals not having a 
partner before the onset of psoriasis, or participants not 
thinking of avoidance before onset and therefore, stating 
that they could not recall. Since these are interesting 
could help to better understand these highly personal 
transitions. 
An association between disease duration and the avoi-
dance of sexual contact was found in this study, which is 
coping mechanisms that may have developed during the 
course of disease. The implications of such mechanisms 
should be further investigated.
Another important point regarding avoidance of 
sexual activities was the perceived pain during sexual 
involvement of psoriasis. Thus, genital psoriasis could be 
an important indicator of sexual avoidance, even when 
excluded due to backward selection (34). In a previous 
study, Ryan et al. also showed that people with genital 
health (29).
Interestingly, we found that the severity of psoriasis in 
of sex, while the severity at the time of study participa-
tion was not. This indicates that participants might have 
due to psoriasis?” as a general tendency rather than a 
current behavior; this may be why there is an association 
with general disease severity, but not with current disease 
severity. Accordingly, the avoidance of sexual contact 
might be a coping mechanism applied by psoriasis pa-
tients (especially those with genital involvement) which 
helps them to avoid feeling shame or having to explain 
the disease to a sexual partner (which were reasons for 
the avoidance of sex mentioned in free text). However, 
it might also indicate the importance of people’s course 
of disease and the personal burden due to high severity, 
even though therapy may reduce visible symptoms. 
Accordingly, an additional measure of disease severity 
Area and Severity Index (PeakPASI), may allow for 
more effective treatment (35). To evaluate the potential 
effect of this measure, more detailed and broader studies 
are necessary.
Free-text reasons given for the avoidance of sexual 
activities due to psoriasis were in line with the reasons 
-
-
rassment… I’ve had one boyfriend make a comment, is 
that, what’s this?” or “The stinging during sex, it is just 
data (36). However, the inclusion of ‘shame’ as the most 
prevalent category represents the importance of internal 
and external stigmatization in the context of visible skin 
conditions (2, 37). 
Study limitations and strengths
several factors should be considered. One main limita-
tion might be a potential selection bias, including a self-
selection bias. Mainly individuals who actively searched 
for health information regarding psoriasis, or received 
a newsletter or updates on social media by multiplier 
institutions might have participated in this survey. Ad-
ditionally, a self-selection bias could have occurred as 
individuals with an impairment of sex life or those with 
on this topic. Furthermore, study promotion via patient 
organization web-pages, social media accounts, and 
mailing systems could have led to a highly vulnerable 
sub-group of individuals with psoriasis. This approach 
might increase diversity in individuals being described 
in the literature as accessibility of different populations 
can be challenging (23). To achieve high acceptance and 
unbiased free-text answers, we did not use validated and 
This might have reduced comparability and generalizabi-
lity. Additionally, the response rate of the most prevalent 
multiplier institution was only 13.9%, when considering 
all individuals receiving the monthly newsletter of the 
patient organization, which led the most individuals to 
participate. This response rate seems considerably low 
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affected individuals, instead of only mentioning it on 
web pages, social media, or e-mail newsletters (38). 
However, it is unclear how many newsletter recipients 
-
interest in psoriasis. Therefore, interpretation of the 
response rate remains rather vague and should be con-
sidered with caution. 
Furthermore, as the study was conducted online and 
participants stated to be diagnosed with psoriasis without 
control of this information, some individuals could have 
made incorrect statements. Even though statements were 
checked for plausibility by logical and time-wise criteria, 
the possibility of incorrect statements cannot be excluded 
with certainty but has to be accepted to widen the public 
health related horizon of populations with psoriasis. Ho-
wever, potential social desirability bias could have been 
minimized by the anonymous nature of this study. In the 
context of sexual content, the direct contact to a physician 
could have impeded participants’ willingness to answer 
exposed (39). Therefore, the use of an anonymous online 
as a localization for occurring pruritus (20% of search 
search for help or information seems to be due to social 
clinical routine (40). Additionally, 25% of participants 
are highly unlikely to have been reported in literature, 
as they do not see a physician for their psoriasis. This 
result is promising and could broaden the spectrum of 
epidemiological descriptions.
Conclusion
The occurrence of genital psoriasis was considerably 
higher in this potential vulnerably subgroup of indi-
viduals with psoriasis compared to other studies, and 
avoidance of sex due to self-given reasons like shame, 
pain and fear of rejection was high. This emphasizes 
the importance of patient organizations when reaching 
out for highly vulnerable groups and individuals who 
do not seek medical help. Furthermore, the subjective 
with the avoidance of sexual activities and the inclusion 
for assessing the individuals’ mental impact or sexual 
impairment of psoriasis.
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SUPPLEMENTARY MATERIAL AND METHODS
Munich and by a team of three epidemiologists and one dermato-
logist; pre-tested by three researchers and three individuals with 
-
avoidance of sexual contact in the context of psoriasis, the usage 
avoidance of sexual avoidance due to psoriasis (‘Do you avoid 
sexual contact due to your psoriasis?’). 
Baseline characteristics of all participants were collected, which 
included age, sex, treating physician (general practitioner, der-
matologist, rheumatologist, no current treatment), duration of 
psoriasis, and subjective disease severity at the time point of 
study participation, as well as subjective overall disease severity. 
Overall severity did not ask for participant’s worst condition since 
onset of psoriasis, but for the subjective general severity over a 
the interpretation of this multi-dimensional construct up to the 
of life aspects. Furthermore, the presence of genital involvement 
affected by psoriasis?’. We did not specify whether only genitals, 
genital and anal area, or anal area as well as groin area were af-
fected, but left it to the interpretation of the participant.
your psoriasis during sexual activities? (Always–Never; 5-point 
partner search or your choice of partner?” (yes, a lot–no, 4-point 
scale). Participants were also asked to declare whether they 
avoided sexual contact since onset of psoriasis (Always–Never; 
5-point scale). If they reported this as at least “sometimes,” they 
were asked to provide a reason or reasons as free text answers 
on a voluntary basis. For the regression analysis, these variables 
were dichotomized with ‘never’ resulting in ‘no,’ and ‘seldom’ to 
‘always’ resulting in ‘yes’. While this might have led to a loss of 
information, the aim of this approach was to facilitate statistical 
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Psoriasis is a chronic skin disease with a high mental burden. Well-known comorbidities include 28
depression, anxiety, as well as alcohol and tobacco addiction, but there is nearly no evidence on other 29
addictions. 30
Objectives31
The aims of this study were to estimate the prevalence of the six most common addictions among 32
psoriasis patients in Germany and to determine associated clinical factors.33
Material & Methods34
Dermatologists working in four dermatological clinics and thirty-two practices across Germany 35
recruited patients between September 2018 and November 2019. This cross-sectional study contained 36
questionnaires on six addictions, depression, anxiety, and the Dermatology Life Quality Index (DLQI). 37
In addition, Psoriasis Area and Severity Index (PASI) was obtained by the physicians. 38
Results39
Overall, 502 patients (43.4% women; mean age: 49.7 ± 14.6 years) were included. Positive screenings 40
for addictions were found in 30.3% of patients for daily smoking, 8.6% for alcohol, 1.2% for gambling, 41
3.8% for Internet, 3.6% for food, and 6.0% for drugs. Younger age was associated with a higher chance 42
of a positive screening for all addictions except for alcohol dependency. The PASI was only significantly 43
associated with smoking. 44
Conclusions45
Addictions seem to be common among psoriasis patients. Further research should include 46
comprehensive data and control groups. Furthermore, standardised screenings and early referrals could 47
represent first steps to improve people-centred healthcare in psoriasis. 48
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INTRODUCTION51
Psoriasis is a chronic inflammatory systemic skin disease associated with typical cutaneous 52
manifestations, affecting 0.5-11.4% of the global population and 2.1% of the German population [1]. It 53
is often accompanied by comorbidities such as cardiovascular, rheumatoid, and mental diseases [2]. 54
Mental diseases are particularly significant in psoriasis, as psoriasis lesions often affect visible body 55
areas or the genital area, causing stigmatisation [3, 4] and impairment of patients’ quality of life, 56
happiness, and sexual life [5–7]. Comorbid mental diseases include depression, anxiety, suicidality, and 57
various addictions [8–13]. Addictions such as alcohol consumption and smoking are commonly 58
investigated [10, 11], whereas data on other addictions like gambling and drug abuse are rare [12]. 59
To improve patients’ quality of life, early detection of these comorbidities is essential. However, 60
comorbidities often remain unrecognised [14–16]. Consequently, there is a great need for improvement 61
to reach the goals outlined in the ‘Global report on psoriasis’ issued by the World Health Organisation 62
(WHO) in 2016 [17]. This report emphasised the need for people-centred care and multidisciplinary 63
approaches in order to minimise the burden that individuals suffer due to psoriasis. When psoriasis is 64
treated sufficiently, a reduction of disease severity has been shown to be associated with an improvement 65
in quality of life and reduction of depressive symptoms [8, 18–20]. Since patient-physician time is 66
limited and limited information on risk factors for mental comorbidities is available, screening for 67
mental comorbidities is promoted in the literature [20, 21]. While some clinical risk factors for 68
depression and anxiety are available [20–23], currently there is no evidence on risk factors for 69
addictions.70
Therefore, the aims of this study were to estimate the prevalence of the six most common addictions in 71




For this cross-sectional, paper-based, non-interventional study, participants were recruited from 32 76
dermatological practices and 4 dermatological clinics across Germany between September 2018 and 77
November 2019. Dermatologists were invited using data from the German psoriasis physician network 78
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‘Psoriasis Praxisnetz Süd-West e.V.’. If physicians agreed to participate, they received material to 79
include up to ten patients. Additional patient sets for inclusion were provided on demand. For study 80
81
psoriasis, able to give written informed consent, and able to answer a German questionnaire. To 82
minimise selection bias, dermatologists were asked to include either (1) the first ten psoriasis patients 83
willing to participate after start of recruitment or (2) patients who visited within the last two months 84
retrospectively and consecutively. Informed consent was obtained from every participant prior to 85
inclusion. The study and all procedures were reviewed and approved by the local ethical committee of 86
the medical faculty of Technical University of Munich (Reference 485/17 S). 87
Questionnaire88
Participants received a questionnaire consisting of the German versions of nine well-established 89
questionnaires for the assessment of mental-health status. A detailed description of each measuring 90
instrument can be found in Appendix S1 and in Table 1. Dermatologists additionally documented patient 91
characteristics including age, sex, body mass index (BMI), and disease severity measured by the 92
Psoriasis Area and Severity Index (PASI). 93
Statistics and data management94
Study size was limited by a patient recruitment time of one year to reduce potential seasonal influences. 95
Descriptive data were generated for general patient characteristics and prevalence of mental disorders. 96
Mental health outcomes for prevalence estimation and further analyses were defined by thresholds listed 97
in Table 1. To test differences between sex, t-test, chi-squared test, or Fisher's exact test were used. 98
Furthermore, logistic regression models were calculated to determine personal and clinical factors (age, 99
sex, BMI, Dermatology Life Quality Index (DLQI), PASI, and positive screenings for depression and 100
anxiety) that were associated with the occurrence of one of the six addictions. Variables were added to 101
multivariate regression models using backward stepwise selection to minimise multicollinearity. Odds 102
ratios (OR) and adjusted OR (aOR) were calculated with the respective 95% confidence intervals (CI). 103
Global alpha was set at 0.05. To improve the quality of the regression models, multiple imputations 104
were conducted. Therefore, a fully conditional specification method was used to impute missing data. 105
In total, five imputations were generated to calculate missing data (n=193; 3.0%). Afterwards, a 106
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sensitivity analysis was performed to compare the results of the multiple imputation analysis with those 107
of the complete cases (i.e., only cases without any missing data; Table S1). All data were entered twice 108
and compared with each other to detect discrepancies. In case of error, source data were accessed and 109
datasets were corrected. IBM SPSS Statistics (Version 25, IBM Corporation, Armonk, NY, USA) was 110
used for all analyses.111
RESULTS112
Patient characteristics113
A total of 502 participants were included in this study. The mean age was 49.7 years (±14.6 years) and 114
218 (43.4%) were women. The mean BMI was 28.1 (±5.4) and the mean PASI was 7.3 (±7.6). Mean 115
DLQI was 7.5 (±7.1), with a significantly higher impairment in women than in men (8.4±7.3 vs. 6.8±7.0, 116
p=0.020). Nearly half of all patients (44.8%) reported no or a small effect of psoriasis on their daily life, 117
whereas 27.1% reported a large or extremely large impact. Overall, 29.5% of individuals screened 118
positive for depression, with 11.4% indicating major depression. Anxiety was found in 48.8% of 119
patients, with 17.5% having signs for an anxiety disorder (Figure 1). Women were more likely to have 120
a positive screening result for depression (35.8% vs. 24.7%, p=0.006) and anxiety disorder than men 121
(20.1% vs. 14.8%; p<0.001, Table 2). 122
Prevalence of addictions123
A total of 152 participants (30.3%) reported daily cigarette smoking, with no significant difference 124
between women and men (33.0% vs. 28.2%, p=0.216, Table 2). The mean duration of daily smoking 125
was 24.2 years (±13.1 years). Of those who are smoking daily, 55.3% (n=84) stated that they smoked 126
less than a pack per day, 34.9% (n=53) one pack per day, and 9.9% (n=15) more than a pack per day. 127
Additionally, 8.6% (n=43) of all patients screened positive for alcoholism, with a higher proportion in 128
men than women (11.3% vs. 5.0%, p=0.020). A sex difference was also observed regarding gambling 129
addiction as only men showed positive screening results (2.2% of men vs. 0% of women, p=0.039). For 130
all other addictions, no sex difference was found. Overall, 3.8% (n=19) of the patients showed 131
pathological Internet behaviour and 2.0% (n=10) had a borderline to pathological Internet consumption. 132
Around 3.6% (n=18) of the patients screened positive for food addiction. Furthermore, 15.0% (n=75) 133
displayed at least a low level of abusive behaviour regarding drugs, with a positive screening of 6.0% 134
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(n=30) for drug abuse (Figure 1). When considering any addiction, 36.9% (n=185) of patients screened 135
positive for at least one addiction, with no significant differences in sex (women: 37.6% vs. men: 36.2%, 136
p=0.200). However, when examining the number of addictions, women were more likely to have one 137
addiction (30.7% vs. 24.3%), while men were more like to have two or more addictions (11.9% vs. 138
6.9%, p=0.013; Table 2).139
Associated factors for addictions140
Expect for alcohol dependency, younger age was associated with a higher chance for a positive screening 141
for each addiction. Thereby, age had the strongest influence on pathological gambling (ORMI = 0.93, 142
95% CI 0.87-1.00) and drug addiction (ORMI = 0.94, 95% CI 0.92-0.97, Figure 1). Additionally, the 143
PASI was positive associated with smoking (ORMI = 1.04, 95% CI 1.01–1.07). For example, a ten-point 144
increase in PASI was associated with a 40% increase in the chance of smoking. Furthermore, depression 145
was significantly associated with alcohol (ORMI = 2.66, 95% CI 1.40-5.01) and drug addiction (ORMI 146
= 2.66, 95% CI 1.23-5.77), whereas chances for Internet (ORMI = 7.66, 95% CI 2.92-19.98) and food 147
addiction (ORMI = 3.03, 95% CI 1.10-8.36) were higher in patients with a positive screening for an148
anxiety disorder (Table S1).149
DISCUSSION150
The aim of this study was to provide evidence on the estimated prevalence of six addictions in patients 151
with psoriasis as well as to identify associated clinical factors. Overall, mental burden was high in 152
patients with psoriasis and there was a high prevalence of addiction with nearly half of the patients 153
reporting signs for at least one addiction. Especially, Internet addiction was surprisingly high in the 154
study population. Younger age was associated with a higher chance for the occurrence of most 155
addictions.156
Comparison to the general population157
The study’s finding indicated that psoriasis patients have a greater likelihood of several addictions 158
compared to representative samples of the German general population, including daily smoking (30.3% 159
vs. 15.1%) [24], alcohol dependency (8.6% vs. 3.1%) [24], pathological gambling (1.2% vs. 0.2%) [25], 160
and legal or illegal drugs abuse (6.0% vs. 3.2%-5.2%) [24]. The increased mental burden due to skin 161
diseases and social withdrawl might play important roles in this association [13, 26]. Despite the higher 162
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BMI in this sample compared to the general population (28.1 vs. 26.7), food addiction was found to be 163
less prevalent among patients with psoriasis (3.6% vs. 7.9%) [27], although the logistic regression 164
revealed a positive association with the BMI. This difference could indicate either a reason other than 165
excessive eating for weight gain in psoriasis patients or the presence of a social desirability bias. 166
Internet addiction is reported to decrease with rising age [28, 29], however, pathological Internet use 167
was higher in this study (3.8%), where the patients’ mean age was 49.7 years, than in a study including 168
a representative sample of German adolescents with a mean age of 14.9 years (3.2%) [30]. Another 169
study performed by Rumpf et al. assessed the Internet addiction among more than 8,130 German 170
individuals, who had a mean age of 39.9 years and used the Internet regularly [28]. When adjusted to 171
the cut-off used by Rumpf et al., the prevalence for Internet addiction was equal in both studies (1.5%), 172
although this study population was older. Accordingly, the study’s findings might indicate an association 173
of Internet addiction with psoriasis, which requires further investigation.174
Comparison to other studies on individuals with psoriasis175
The proportion of psoriasis patients that currently smoke varies widely in the literature, ranging from 14.0% 176
to 51.3% [10]. Although the prevalence detected in this study was within this range, it was lower compared 177
to that reported in another German study among psoriasis patients (30.8% vs. 41.0%) [12]. In a systematic 178
review, the prevalence of alcohol addiction was reported to be between 11.1% and 28.0% in psoriasis patients 179
[11], which is higher than that reported in this study. One study that also used the CAGE score to assess 180
alcohol addiction reported a prevalence of 18.3% among psoriasis patients [31]. A reason for that 181
considerable higher prevalence might be the fact that only 60 patients with psoriasis were investigated. 182
Another study including psoriasis patients from a dermatological clinic and also assessing alcohol 183
dependency via the CAGE questionnaire reported an estimated prevalence of 13.5% [12]. Although the 184
prevalence of alcohol addiction was lower in this study compared to most of the previous studies, the 185
prevalence I exceeded the rate found within the German general population (3.1% [24]). 186
In comparison to the general population, the prevalence of Internet addiction was higher among the included 187
psoriasis patients, however the prevalence was lower in comparison to another study including individuals 188
with psoriasis reached via online self-help groups (8.5%) [26]. As the prevalence was even higher in people 189
with psoriasis than in patients with psoriasis, the results underline the importance of a people-centred care as 190
demanded by the WHO [17]. 191
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When considering compulsive gambling, food addiction, and drug abuse, reported data on individuals with 192
psoriasis are limited to one study performed by Zink et al., which included 102 patients from a university 193
hospital [12]. While compulsive gambling was higher than in the present sample (2.0% vs. 1.2%), food 194
addiction (3.1% vs. 3.6%) and drug addiction (1.0% vs. 2.4%; threshold adapted to Zink et al.) were lower 195
than in this sample. As there were no considerable differences regarding age and severity of psoriasis, the 196
different findings emphasise the need for further clarification and research potentially including data 197
extracted from health insurances.198
Although patients included in this study had lower values for PASI and DLQI compared to a study by Lamb 199
et al. [18], the prevalence found for depression and anxiety were higher than in the other study, who found 200
that 9.9% of their psoriasis patients were likely to have major depression and 13.1% a generalised anxiety 201
disorder. Another study by Delgard et al. [32] found a comparable prevalence of 13.8% for depression, but a 202
higher prevalence for anxiety (22.7%). Interestingly, Delgard et al. reported depression and anxiety to exhibit 203
aORs of 3.0 and 2.9 in patients with psoriasis when compared with healthy controls, which emphasises the 204
mental impairment caused by psoriasis [32].205
Associated factors for addictions206
There was no previous study that investigated individual and clinical factors associated with all the six 207
addictions. The multiple regression models revealed that for most of the addictions, younger age had a 208
significantly influence. Although age is discussed highly controversial in terms of addiction within the 209
current literature [33, 34], it stands out that for all addictions, expect for alcohol addiction, the chance 210
of being screened positive significantly decreased with rising age. While being controlled via backward 211
selection, only daily smoking was associated with a higher PASI. This might either indicate the absence 212
of a classical dose-response relationship or that conventional strategies to classify disease severity in a 213
cross-sectional manner might not comprehensively reflect the individual burden experienced by patients 214
[35]. Furthermore, all addictions apart from smoking and gambling were associated with depression or 215
anxiety, which is in accordance with the literature [36]. These findings strengthen the reliability of the 216
study results. However, no certain clinical factor can be identified as potential predictor and reported 217
prevalence remain higher than those reported within the general population. Therefore, the findings also 218
emphasise the need for further research and standardized screenings.219
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Strengths and limitations220
A major strength of this study is the large number of patients and a strict set of rules for consecutive 221
inclusion of patients was applied to reduce selection bias. Additionally, recruitment was carried out in 222
36 medical settings throughout Germany. There are some study limitations, however. First, there is a 223
potential for selection bias as participation for dermatologists was voluntary and this can lead to a self-224
selected subgroup of dermatologists. Second, screening for addictions was performed using standardised 225
questionnaires without a corresponding control group, so that comparisons are only indirect. Although 226
the questionnaires are validated and all showed acceptable results for specificity and sensitivity [3], it 227
has to be taken into account that these findings do not represent diagnoses but rather estimate the 228
respective outcomes. Third, a certain degree of social and desirability bias needs to be considered. 229
Patients are not always willing to disclose information regarding sensitive and potentially stigmatising 230
data [37, 38].231
Conclusion232
In conclusion, the prevalence of addictions, especially Internet addiction, was high among patients with 233
psoriasis. To verify the association between the prevalence and psoriasis, future research should also 234
include a suitable control group or claims data. The study findings underline the importance of 235
implementing a routine, not too time-consuming assessments of psychological comorbidities when 236
assessing psoriasis severity, which could be easily implemented in psoriasis care [21–23]. As different 237
clinical variables were associated with the occurrence of different addictions, a possible first step could 238
include routine and standardised screening as well as referral for early detection and treatment of these 239
psychological disturbances to improve the quality of people-centred care.240
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Table 2: General characteristics of participants stratified by sex. Differences were compared using 349
unpaired t-test and Chi square test. SD=Standard deviation; BMI=Body-Mass-Index; 350








[n (%)] Mean ± SD [n (%)] Mean ± SD [n (%)] Mean ± SD
Age 49.7 ± 14.6 50.7 ± 14.8 48.9 ± 14.4 0.164
BMI 28.1 ± 5.4 28.3 ±6.5 28.0 ± 4.3 0.594
PASI 7.3 ± 7.6 6.7 ± 6.8 7.8 ± 8.1 0.098
DLQI 7.5 ± 7.1 8.4 ± 7.3 6.8 ±7.0 0.020
Depression
No 351 (69.9) 139 (63.8) 212 (75.2)
0.006
General 91 (18.1) 43 (19.7) 48 (17.0)
Major 57 (11.4) 35 (16.1) 22 (7.7)
Missing 3 (0.6) 1 (0.5) 2 (0.7)
Anxiety
No 248 (49.4) 84 (38.5) 164 (57.7)
< 0.001
Mild 157 (31.3) 83 (38.1) 74 (26.1)
Moderate 68 (13.5) 36 (16.5) 32 (11.3)
Severe 20 (4.0) 10 (4.6) 10 (3.5)
Missing 9 (1.8) 5 (2.3) 4 (1.4)
Daily 
smoking
Yes 152 (30.3) 72 (33.0) 80 (28.2)
0.216No 343 (68.3) 142 (65.1) 201 (70.8)
Missing 7 (1.4) 4 (1.8) 3 (1.1)
Years of 
smoking
24.2 ± 13.1 25.3 ± 13.3 23.3 ± 12.9 0.355
Alcohol
Yes 43 (8.6) 11 (5.0) 32 (11.3)
0.020No 444 (88.4) 195 (89.4) 249 (87.7)
Missing 15 (3.0) 12 (5.5) 3 (1.1)
101
Gambling
Yes 6 (1.2) 0 (0.0) 6 (2.1)
0.039*No 481 (95.8) 210 (96.3) 271 (95.4)
Missing 15 (3.0) 8 (3.7) 7 (2.5)
Internet
No 449 (89.4) 195 (89.4) 254 (89.4)
0.583
Borderline 10 (2.0) 4 (1.8) 6 (2.1)
Pathological 19 (3.8) 6 (2.8) 13 (4.6)
Missing 24 (4.8) 13 (6.0) 11 (3.9)
Food
No 475 (94.6) 205 (94.0) 270 (95.1)
0.423
Mild 7 (1.4) 5 (2.3) 2 (0.7)
Moderate 4 (0.8) 1 (0.5) 3 (1.1)
Severe 7 (1.4) 3 (1.4) 4 (1.4)
Missing 9 (1.8) 4 (1.8) 5 (1.8)
Drugs
No 406 (80.9) 174 (79.8) 232 (81.7)
0.484
Low level
45 (9.0) 22 (10.1) 23 (8.1)
Moderate 
level
18 (3.6) 5 (2.3) 13 (4.6)
Severe level 8 (1.6) 2 (0.9) 6 (2.1)
Substantial 
level
4 (0.8) 2 (0.9) 2 (0.7)
Missing 21 (4.2) 13 (6.0) 8 (2.8)
Addictions
None 250 (49.8) 95 (43.6) 155 (54.6)
0.013
One 136 (27.1) 67 (30.7) 69 (24.3)
Two 36 (7.2) 14 (6.4) 22 (7.7)
Three or 
more
13 (2.6) 1 (0.5) 12 (4.2)
Missing 67 (13.3) 41 (18.8) 26 (9.2)




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix S1. Supplementary information on questionnaire methodology359
Dermatology Life Quality Index360
Disease-specific quality of life was measured using the Dermatology Life Quality Index (DLQI; 361
-0.92) [1–3]. It is a commonly used questionnaire including 10 questions such as 362
‘Over the last week, how itchy, sore, painful, or stinging has your skin been?’ and ‘Over the last week, 363
how much has your skin created problems with your partner or any of your close friends or relatives?’. 364
Questions can be answered on a scale ranging from ‘not at all’ (0) to ‘very much’ (3) and the scale 365
ranges from a minimum of 0 to a maximum of 30. Overall, the range from 0 to 1 indicates ‘no effect at 366
all on patient’s life’, while 2 to 5 indicates a mild, 6 to 10 a moderate, 11 to 20 a large, and 21 to 30 an 367
extremely large effect on the patient’s life [1].368
World Health Organization (WHO)-Five Well-Being Index 369
Depression was assessed using the International Classification of Diseases (ICD)-10-based WHO-Five 370
Well- –6]. It is a validated, standardised, and widely used 371
questionnaire consisting of five questions on an individual’s wellbeing like ‘I have felt calm and relaxed’ 372
or ‘My daily life has been filled with things that interest me’. Answers range from ‘All of the time’ (5) 373
to ‘At no time’ (0), and all answers are multiplied by 4 to reach a score between 0 and 100. Lower values 374
indicate a poorer outcome for the individual’s well-being. When used as a screening tool for depression, 375
it yields a sensitivity of 0.86 and a specificity of 0.81 at a cut-376
sensitivity of 0.94 and a specificity of 0.83 for a cut-377
estimations for both cut-offs were calculated.378
Generalized Anxiety Disorder 7-item Assessment379
The Generalized Anxiety Disorder 7-item (GAD-380
assessment of anxiety [8, 9]. It contains seven questions considering the Diagnostic and Statistical 381
Manual of Mental Disorders (DSM)-IV criteria containing questions on topics like having trouble 382
relaxing and becoming easily annoyed or irritable. Each question is ranked on a 4-point Likert scale 383
ranging from ‘Not at all’ (0) to ‘Nearly every day’ (3). Accordingly, the score ranges between 0 and 21. 384
It distinguishes between mild (5-9), moderate (10-14), and severe (15-21) anxiety. For further analyses, 385
a cut-off point of 10 or higher was defined to determine the presence of a generalised anxiety disorder. 386
This cut-off value previously showed a sensitivity of 89% and a specificity of 82% [9].387
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CAGE-questionnaire388
A possible alcohol use disorder was determined using the DSM-based CAGE-questionnaire (CAGE, r 389
= 0.89 at presented cut-off) [10, 11]. The letters in CAGE refer to the initial letters of the 4 respective 390
questions. The questionnaire addresses an individual’s drinking behaviour, focusing on ‘Cutting down’, 391
‘Annoyed by criticism’, ‘Guilt about drinking’, and alcohol as an ‘Eye-opener’ in the morning. If at least 392
two of these questions were answered with ‘yes’, the patient was considered as potentially having an 393
alcohol use disorder. The questionnaire yields an average sensitivity of 0.71 and specificity of 0.90 [12].394
Smoking395
Smoking was assessed by the question ‘Do you smoke?’. Participants were subsequently asked to 396
declare whether they smoked ‘seldom’, ‘daily, less than a pack, ‘daily, one pack of cigarettes’, ‘daily,397
1.5 packs of cigarettes’, or ‘daily, more than 2 packs of cigarettes’. A pack of cigarettes was predefined 398
as 20 cigarettes. Participants with daily smoking habits were considered as smokers for further analyses. 399
All participants who smoke were additionally asked to declare for how many years they have been 400
smoking. 401
Gamblers Anonymous 20 Questions402
The occurrence of a pathological gambling behaviour was determined using the Gamblers Anonymous 403
-0.94) [13, 14]. This questionnaire is comparable to the DSM-404
IV diagnostic criteria and contains 20 questions on an individual’s gambling habits. Answers are 405
dichotomous and add up to a score ranging from 0 (all questions answered no) to 20 (all questions 406
answered yes). The cut-off407
Subsequently, individuals answering seven or more questions with yes were considered addicted to 408
gambling. 409
Compulsive Internet Use Scale 410
Pathologic behaviour regarding Internet use was quantified by the Compulsive Internet Use Scale 411
412
of control’, ‘preoccupation (including behavioural and mental factors)’, ‘withdrawal symptoms’, 413
‘coping or mood modification’, and ‘conflict’. Answers were given on a 5-point Likert scale ranging 414
from ‘never’ (0) to ‘very often’ (4). The scale ranges from 0 to 56 and the cut-offs for borderline use 415
ely. Higher values indicate higher addiction 416
to the Internet.417
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Modified Yale Food Addiction Scale 2.0418
For the occurrence of any food addiction or eating disorder, the abbreviated version of the Yale Food 419
Addiction Scale 2.0 (mYFAS 2.0, Kuder– 0.86) was used [17]. It contains questions 420
focusing on relevant DSM-V criteria such as ‘I ate to the point where I felt physically ill’ and ‘I tried 421
and failed to cut down on or stop eating certain foods’. It describes 11 symptoms, and two items survey 422
impairment and distress. Items are answered using a 7-point scale ranging from ‘Never’ (0) to ‘Daily’ 423
(7) and classification for relevance differs between items. Therefore, some items are deemed relevant if 424
they are answered with (2) to (7) (e.g. items 6 and 12), while others are deemed relevant if answered 425
with (4) to (7) (e.g. items 4 and 8) or (5) to (7) (e.g. items 2 and 5). The computed score of symptoms 426
ranges from 0 to 11. If at least one item describing impairment or distress was present at least 2 to 3427
times per week, a score of 2 to 3 could be considered as a mild, a score of 4 to 5 as a moderate, and a 428
score of 6 to 11 as a severe eating disorder. For further analyses, the combination of impairment or 429
distress plus a score of 2 or higher was considered ‘diagnostic’ for a food addiction [17, 18]. 430
Drug Abuse Screening Test431
The Drug Abuse Screening Test (DAST- -0.94) was used to screen for drug 432
abuse [19–21]. The DAST-10 contains questions like ‘Have you used drugs other than those required 433
for medical reasons?’ and ‘Have you engaged in illegal activities in order to obtain drugs?’ and is based 434
on DSM-III criteria. Questions are answered with either yes or no. Item number 3 (‘Are you always able 435
to stop using drugs when you want to?’) was coded reverse. If participants indicated not using illegal 436
drugs, but responded ‘no’ to that question, the answer was not counted. Subsequently, no positive answer 437
indicated no problem, whereas 1 to 2 positive answers indicated a low, 3 to 5 a moderate, 6 to 8 a 438
substantial, and 9 to 10 a severe problem [19, 20]. For further analyses, a cut-off value of 3 or more 439
positive answers was considered as a positive screening result [20, 21].440
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Hair loss is a symptom that can cause stigmatization and severe impairment of quality 
of life. The aim of this systematic review was to evaluate the literature on stigmatizati-
on of hair loss. Using predefined MeSH terms and keywords, a systematic search was 
performed in the databases MEDLINE (PubMed), EMBASE, PsycINFO and PsycNET. No 
time restriction was chosen (last update: May 07, 2019; PROSPERO registration num-
ber: CRD42019122966). A total of 98 studies were identified, of which eleven were 
selected for inclusion in this work. The Hairdex, a questionnaire on disease-specific 
quality of life, was the most frequently used instrument for the quantitative assess-
ment of stigma. The studies were highly heterogeneous and values for stigmatizati-
on of androgenetic alopecia varied widely. However, regardless of the pathogenesis, 
patients with hair loss often suffer from stigmatization which limits their quality of 
life. Stigmatization of people with visible skin lesions has often been neglected in 
clinical practice and in daily contact with affected individuals. Studies that specifically 
address the stigma of hair loss are rare. Further studies are needed to achieve compa-
rability within pathogeneses as well as with other visible dermatoses in order to better 
understand the enormous psychosocial burden of hair loss.
Stigmatization caused by hair loss – a 
systematic literature review
Background
Hair loss is, irrespective of its pathogenesis or severity, a 
cause of distress for affected individuals that is often un-
derestimated by outside parties [1–3]. Pathogeneses vary 
and include androgenetic alopecia, alopecia areata, dif-
fuse alopecia, and therapy-induced hair loss [4, 5]. While 
modern therapies are on the advance [6–8], affected indi-
viduals often suffer from internalized and external stigma-
tization in addition to a reduced quality of life and a large 
number of psychological comorbidities due to their changed 
appearance [4, 9]. Stigmatization describes a phenomenon 
that excludes affected individuals from complete social ac-
ceptance. This phenomenon may be triggered by the pati-
ents themselves (internalized stigma), or it may be induced 
by their environment (external stigma) [10]. Given the hea-
vy burden on affected individuals, stigmatization may then 
result in psychological diseases [4] and severely impair the 
quality of life [11]. Dermatological disorders are common 
[12], and because of stigmatization in case of visible skin ch-
anges and its impact on the life of many affected individu-
als, the German Federal Ministry of Health (BMG) initiated 
the project initiative “In meiner Haut” (in my skin) for the 
destigmatization of people with visible skin alterations [13]. 
In this context, an expert panel consisting of patient repre-
sentatives, scientists and physicians currently develops and 
scientifically evaluates various formats of intervention in 
order to reduce stigmatization due to visible skin diseases. 
For an evidence-based approach, it is essential to obtain an 
overview of the existing literature to determine the need 
and plan for interventions, where necessary. Accordingly, it 
is the aim of this systematic review to compile a structured 
summary of the literature on internalized and external stig-
matization due to hair loss.
Material and Methods
This systematic review was conducted according to the gui-
delines of Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) [14] and Meta-Analysis of 
Observational Studies in Epidemiology (MOOSE) [15]. Pri-
or to execution, the underlying protocol was registered in 
the PROSPERO database for systematic reviews (registration 
number: CRD42019122966) [16].
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited and is not used for commercial purposes.
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Search strategy and selection process
The databases MEDLINE (PubMed), EMBASE, PsycIN-
FO, and PsycNET were searched systematically by means 
of predefined search terms consisting of Medical Subject 
Headings (MeSH-terms) terms and other selected keywords. 
The following search terms were used: “alopecia”, “stigma”, 
and “humans”, as well as corresponding alternative terms 
(Table 1). In addition, the source references of the full pu-
blications in the last stage of the selection process were ma-
nually searched for additional suitable publications. No time 
restriction was chosen (last update: May 07, 2019).
All identified articles were assessed by two indepen-
dent reviewers (MS and LT; both MPH and PhD students). 
In phase I of the selection process, titles and abstracts were 
read and evaluated based on predefined criteria. In pha-
se II, the full texts of those studies assessed as relevant 
during phase I were evaluated and reviewed with respect to 
inclusion and exclusion criteria (Figure 1). Discrepancies 
were discussed and, in case of disagreement, a consensus 
was reached in consultation with a third reviewer (AZ; PD 
Dr. Dr. med., MPH; senior physician). If the full text was 
not available, the corresponding author was contacted by 
e-mail.
Table 1 Conception of the used search term according to respective guidelines.
Core concepts Concept 1 Concept 2 Concept 3 Concept 4















 Alopecia Areata totalis
 Alopecia Areata universalis
 Alopecia Areata/epidemiology
 Alopecia Areata/mental health*
 Alopecia Areata/psychology*
 Alopecia Areata/therapy*








 Frontal fibrosing alopecia
 Hair Loss
 Ophiasis





















(Adolescent OR Adult OR Aged OR Child OR Female OR Humans OR Male OR Middle Aged OR Young 
Adult) AND (Internalised Stigma OR Internalized Stigma OR Perceived stigma OR Self-Stigma OR Social 
Stigma* OR Stereotyping OR Stigma OR Stigma, social OR Stigmata OR Stigmatising OR Stigmatization 
OR Stigmatisation OR Stigmatize) AND (alopecia OR alopecia areata OR alopecia areata totalis OR alope-
cia areata universalis OR alopecia areata/epidemiology OR alopecia areata/mental health* OR alopecia 
areata/ psychology* OR alopecia areata/ therapy* OR alopecia areolar syphilitic OR alopecia/chemically 
induced* OR alopecia/ psychology* OR alopecia/ rehabilitation* OR androgenetic alopecia OR bald 
head OR bald OR effluvium OR frontal fibrosing alopecia OR hair loss OR ophiasis postmenopausal fron-
tal fibrosing alopecia OR telogen effluvium OR Trichotillomania) AND ((english [language]) OR (german 
[language])).
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Inclusion criteria
All study designs (quantitative and qualitative studies) were 
considered for this review. Studies were assessed as relevant 
during phase I and phase II if they (i) addressed external or 
internalized stigmatization of individuals with hair loss, or 
(ii) included health-related stigma due to hair loss as depen-
dent or independent variable.
Exclusion criteria
Studies were excluded in phase II if they (i) were not available 
in the English or German language, (ii) consisted of an edi-
torial, comment, or study protocol, (iii) did not present any 
own data, or (iv) addressed exclusively stigma not attributed 
to hair loss (for example, stigmatization due to gender, sexu-
ality, or ethnic group).
Data collection and quality assessment
The data extraction and study assessment described below 
was performed independently by both MS and LT. Where 
present, the following data were extracted from each study: 
title, last name of first author, year of publication, type of 
article (full publication/abstract), study design, methodology 
and instruments of data acquisition, patient number, and col-
lected outcome variables.
All included cross-sectional studies were assessed by two 
authors (MS, LT) with the checklist Strengthening the Repor-
ting of Observational Studies in Epidemiology (STROBE) 
[17]. Qualitative studies were assessed with the checklist 
Consolidated Criteria for Reporting Qualitative Research 
(COREQ) [18]. The development version of the STROBE 
checklist for conference abstracts was used to assess publica-
tions only available as abstracts [17].
The quality of a study was assessed based on the propor-
tion of described subitems considered relevant and reported in 
the corresponding checklist: A (very good) > 80 %, B (good) 
80–50 % and C (too inaccurate) < 50 % [19]. In case of discre-
pancy, the two quality assessments were discussed and, if no 
consensus was reached, AZ was included in the final decision. 
The interrater reliability between MS and LT was 54.5 %, and 
any disagreement could be resolved without assistance by AZ. 
Exclusion due to inferior quality of articles was not predefined.
Results
The systematic literature search in the four databases identi-
fied 98 publications. After exclusion of publications based on 
titles and abstracts, 16 articles remained for examination of 
































Identification of potential articles in the data bases
PubMed
90
Identified articles without duplicates
(phase I)
98
Studies eligible for the review
10
Studies included in the review
(2 poster abstracts, 3 qualitative studies,
5 quantitative cross-sectional surveys, 1 cohort study)
11
Full texts of publications read and reviewed
based on inclusion and exclusion criteria
(phase II)
16
Full texts excluded (6)
- stigma not measured (2)
- review (1)
- validation study (1)
- stigma not related to hair loss (2)
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the full texts. Another study was identified by manual search 
of the reference lists in the inspected full publications. After 
evaluation of the full texts, eleven studies were included in 
this review (Figure 1).
The characteristics of the included studies and their as-
sociated authors are described in Table 2. The majority of 
the articles came from Europe (5/11) and Turkey (3/11) and 
were predominantly published in dermatological (5/11) and 
psychological (3/11) journals. The average number of authors 
per publication was 5.5, and most first authors were affiliated 
with a dermatological or psychological institution (36.4 % 
each). The median impact factor of the included scientific 
journals was 3.117 with a range from 0.884 to 8.017. The 
articles were published in ten different journals. Two of the 
identified articles were published in the International Journal 
of Trichology (Table 2). The included publications comprised 
two poster abstracts [20, 21], three qualitative studies [22–
24], five quantitative cross-sectional surveys [25–29], and 
Table 2 Overview over the characteristics of included articles and authors (n = 11).
General characteristics of the included articles n (%)
Authors Number of authors 13 3 (27.3)
46 4 (36.4)
> 6 4 (36.4)
Countries of institutions of the 











Scientific journals Topics of scientific journals Dermatology 5 (45.5)
Psychology 3 (27.3)
Oncology 2 (18.2)
Patient-centered medicine 1 (9.1)
Titles of scientific journals International Journal of Trichology 2 (18.2)
Anais Brasileiros De Dermatologia 1 (9.1)
British Journal of Dermatology 1 (9.1)
Cancer Nursing 1 (9.1)
European Journal of Cancer 1 (9.1)
European Psychiatry 1 (9.1)
Health Psychology 1 (9.1)
JAMA Dermatology 1 (9.1)
Journal of Investigative Dermatology 1 (9.1)
Patient Education and Counseling 1 (9.1)
Impact factor 2017 (median, range) 3.177 (0.8848.107)
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one retrospective cohort study, which, however, presented 
only a cross-sectional report on stigmatization [30]. Subdi-
vided according to the pathogenesis underlying hair loss, five 
studies focused on therapy-induced hair loss (chemotherapy 
or endocrine therapy) [20, 22–24, 30], four on androgenetic 
alopecia [25, 27–29], three on alopecia areata [21, 25, 29], 
and one on diffuse alopecia [28] (Table 3).
Measuring instruments
The Hairdex [11] was used in four of the eight quantitati-
ve studies and thus the most frequently utilized instrument 
[25, 27, 28, 30]. It consists of 48 questions, such as “The 
condition of my hair impairs my societal and social life” or 
“The condition of my hair makes it more difficult for me to 
achieve as much as usual”, and is specifically concerned with 
the impairment of the quality of life due to hair loss. The fac-
tor of stigmatization is evaluated with a subscale consisting 
of eight questions (Cronbach's α of 0.68 [11]). For each ques-
tion, affected individuals assess on a five-step Likert scale to 
what degree statements such as “The condition of my hair 
is disfiguring me” apply to them. Subsequently, the achieved 
scores for both total scale and individual subscales are line-
arly transformed into a value range from 0–100 with higher 
values indicating more severe impairment.
Only three studies used measuring instruments 
specifically developed for measuring stigma. Specifically, the 
Internalized Stigma Scale (ISS, Cronbach’s α for psoriasis: 
0.65–0.78) [21], the Feelings of Stigmatization Questionnai-
re (Cronbach's α for alopecia areata: 0.93) [26], and a com-
bination consisting of a modified Stroop test and two appro-
ach-avoidance tasks [29] were used. In one poster abstract, 
the measuring instrument used for the determination of stig-
matization was not comprehensible [20]. The categorization 
of the measuring instruments with respect to assessment of 
internalized and external stigma is depicted in Table 4.
Alopecia areata and androgenetic alopecia
A study by Temel et al. [21] showed a significant correlati-
on between stigmatization due to alopecia areata and both 
the Dermatology Life Quality Index (DLQI; r = 0.508) and 
general mental health measured with the General Health 
Questionnaire (GHQ; r = 0.329). The scores for internalized 
stigmatization measured with the ISS [31] were comparable 
to the scores of patients with acne vulgaris and higher than 
those of patients with vitiligo (59.5 vs. 59.5 vs. 51.7) [21].
In another study, patients with various forms of hair loss 
(54 % alopecia universalis, 18 % alopecia totalis, 26 % alope-
cia areata, 2 % androgenetic alopecia) and their partners 
were examined by a combination of a modified Stroop test 
and two approach-avoidance tasks to quantify internalized 
and external stigma. The results of this study indicate that 
patients with hair loss are affected more by internalized 
stigmatization while patients with psoriasis rather react to 
stimuli that imply external stigma [29].
A third study compared alopecia areata and androgenetic 
alopecia [25]. Although, based on the Hairdex, patients with 
alopecia areata report a lower impairment of their quality of 
life (57.0 vs. 68.4; p = 0.025), no statistically significant dif-
ference was found on the stigmatization subscale (4.7 vs. 5.6; 
p = 0.372). Overall, there was a correlation between disease 
duration of alopecia areata and a higher impairment of the 
quality of life due to stigmatization (r = 0.54; p = 0.001). In 
both groups, women seem to experience more stigmatizati-
on, although this finding was not significant [25]. Moreover, 
when directly compared to patients with psychiatric disea-
ses, such as depression or anxiety disorders, patients with 
alopecia areata showed a higher degree of stigmatization 
(74.1 ± 23.5 vs. 52.0 ± 24.3; p < 0.01) [26].
According to a study by Sawant et al. [27] that addres-
sed androgenetic alopecia exclusively in men, younger and 
less severely affected men were less impaired by stigmati-
zation [Hairdex subscale: 13.2 vs. 13.9 and 13.0 vs. 13.9] 
[27]. Another study on women with diffuse or androgenetic 
alopecia showed that patients with a highly visible form of 
diffuse alopecia were more severely affected by stigmatizati-
on than those with mild alopecia (37.8 vs. 16). The perceived 
stigmatization of affected patients increased steadily with in-
creasing severity of androgenetic alopecia (20.1 to 26.9) [28].
Therapy-induced alopecia
Approximately half of the studies (5/11) addressed hair loss 
induced either by preceding chemotherapy for various tu-
mors [20, 22–24] or endocrine therapy for breast cancer [30]. 
The quantitative assessments showed that 30.4 % of the pa-
tients considered hair loss as the most distressing side effect 
and that loss of hair resulted in stigmatization with impaired 
social interactions in 45.8 % of the patients [20]. Moreover, 
Freites-Martinez et al. [30] observed a mean Hairdex score 
of 14.6 (± 17.0) on the subscale for stigmatization while the 
score for the total Hairdex was 25.6 (± 14.5). Quantitative 
studies indicated psychological stress due to stigmatization, 
too. For example, patients were cited with statements such 
as “I think the worst thing that bothered me was people 
used to look at me and be sort of ‘‘aah.’’ And then they sort 
of say, ‘‘for the grace of God it's not me’’…” (female pati-
ent, 61 years, England) [23]. The experienced stigmatizati-
on was also described by statements such as “Our cultural 
environment extremely values women's [healthy] looks and 
it doesn't allow us to show ourselves as we are…” (female 
patient, 59 years, Italy) [24]. Affected individuals often try 
to hide the occurring hair loss [22]. This was often done by 
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wearing a wig and was associated with positive statements 
such as “I'd had enough sort of that I did get a wig which 
was great.” (Female patient, 61 years, England) [23]. In this 
context, an accompanying program for patients with thera-
py-induced alopecia was described as a potentially positive 
addendum for improving quality of life and minimizing in-
ternalized stigma [24].
Discussion
To our knowledge, this systematic review is the first work 
providing an overview of the evidence of stigmatization in 
individuals with hair loss. In the available literature, only ele-
ven publications were assessed as relevant for this topic. Irre-
spective of the cause of hair loss, it is, however, evident that 
affected individuals frequently suffer from internalized and 
external stigmatization. With respect to internalized stigma, 
hair loss is comparable to acne vulgaris and psychiatric di-
seases, such as depression and anxiety disorders. Internalized 
stigma is, however, more pronounced than, for example, in 
vitiligo.
Due to the fact that hair loss may occur as a symptom of 
several diseases, based on various pathogeneses and with dif-
ferent severity, the identified studies were very heterogeneous 
[5]. When comparing the studies, it became evident that the 
reported diminished quality of life due to stigma, as measu-
red by the Hairdex, varied not only between pathologies but 
also between study populations (alopecia areata: 4.7 [25]; 
diffuse alopecia: 16.9 to 37.8 [28]; androgenetic alopecia: 
5.6 [25] to 20.1 and 26.9, respectively [28]). Based on these 
findings, patients with diffuse alopecia [28] and women [25] 
seem to suffer more severely from stigmatization. Further-
more, almost half of the studies addressed hair loss as con-
sequence of an already existing and treated disease, that is, 
hair loss as side effect. Given that this aspect is important for 
interpretation of the study results, the corresponding results 
are discussed separately.
Measuring instruments
Most studies used the Hairdex developed by Fischer et al. (Ta-
ble 3) [11]. Given that this is a scale for assessing the quality 
of life that measures stigmatization only as subscale, these re-
sults are difficult to compare with the Feelings of Stigmatiza-
tion Questionnaire [26] or the ISS [21], which are specifically 
designed to assess stigmatization. While the overall construct 
of the Hairdex is validated by DLQI and GHQ, it should be 
taken into account that no comparable scale was used to mea-
sure stigmatization when interpreting the subscale for stigma-
tization. Furthermore, the Hairdex has only been validated 
in German, though it was also used in other languages. In 
addition, none of the included publications gave any infor-
mation on the transformation of the scores for total scale or 
subscales to the value range of 0–100. The corresponding au-
thors were contacted to clarify this aspect. Three of the four 
authors responded. One author confirmed transformation of 
the subscale [28], while two authors reported that they did 
not make any transformation [25, 27]. This reduces both the 
informative value and the comparability of the results, thus 
excluding direct comparison of the studies and adequate indi-
vidual evaluation of the scores and in consequence immensely 
diminishing the informative value of this review. Furthermo-
re, the statement “So far, I have not been taken seriously at all 
by my physician” within the stigmatization subscale implies a 
need of action with respect to recognition of the psychosocial 
burden by medical personnel. However, exact scores for this 
question were not reported.
With respect to the stigma-specific questionnaires, it 
should be noted that the ISS was developed for assessing 
stigmatization in psychiatric diseases and has not yet been 
validated in the field of dermatology. Within the present 
sample, however, it showed plausible scores and good inter-
nal consistency, in turn suggesting good reliability [21]. In 
addition, the Feelings of Stigmatization Questionnaire was 
utilized, a tool that has been used for skin diseases in the 
Table 4 Measuring instruments used for the quantitative depiction of stigma and their dimensions in relation to stigmatization.





Hairdex [25, 27, 28, 30] X
Feelings of Stigmatization Questionnaire [26] X X
Internalized Stigma Scale (ISS) [21] X X
Modified Stroop test [29] X
Approach-avoidance tasks [29] X
*From the information provided in the literature, it is not possible to conclude whether internalized or external stigmatization 
is measured.
120
Review Article Stigmatization caused by hair loss
11© 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft. | JDDG | 1610-0379/2020
past. While its subscales have been validated for patients 
with psoriasis and show good consistency [32], they have 
no proven quality in the two study groups of psychiatric di-
seases and alopecia. This must be taken into account when 
interpreting the results. Another measuring instrument was 
the combination of a modified Stroop test and two appro-
ach-avoidance tasks. These instruments are embedded in 
psychological behavioral research and are well suited to 
assess stigmatization and its nature – internalized or ex-
ternal – without using a questionnaire [29]. In summary, 
measuring instruments for both external and internalized 
stigmatization are covered in the literature. However, these 
are either not validated or not easily comparable due to the 
heterogeneity of the studies.
Hair loss as symptom
Overall, the scores for the subscale of the Hairdex questi-
onnaire [11] vary strongly between both the various pathoge-
neses and the various study populations. According to these 
results, patients with diffuse alopecia (16.9–37.8) [28] and 
women (androgenetic alopecia, women vs. men: 6.4 vs. 4.2; 
p = 0.078) [25] are more severely affected by stigmatization. 
The comparability of the studies is, however, limited, given 
that cultural influences, differences in gender distribution, and 
uncertain methodology regarding the use of the Hairdex may 
have affected the study outcomes. For example, only in Tur-
key was more than one of the relevant studies conducted and 
published. In general, however, the results underscore the psy-
chosocial burden that can be triggered by hair loss [4, 9, 33].
Therapy-induced hair loss  hair loss as adverse 
event
Only one study used the Hairdex for the quantitative analy-
sis of therapy-induced hair loss [30]. The corresponding score 
for stigmatization was comparable with the scores for andro-
genetic alopecia [27] or slightly visible diffuse alopecia [28]. 
While the heterogeneity of the populations and the use of a 
modified and non-validated form of the Hairdex have to be ta-
ken into account again, the qualitative studies underscore the 
findings indicating a high burden due to stigmatization [22–
24]. While qualitative studies also often indicate the perceived 
stigmatization due to stares of others, no quantitative studies 
on this aspect exist in the literature. Furthermore, there are no 
quantitative differentiations between tumor classes or strate-
gies of how patients have dealt with stigmatization.
Limitations and integration into the general context
Possible limitations of this review are the low number of 
publications, a potential publication bias and the lack of 
studies on minors, although it is well-known that hair loss 
may also occur at this vulnerable age [34]. Furthermore, 
the quality of the included studies varied strongly, which 
may have affected the informative value of this review. Ho-
wever, we decided against retrospective exclusion of qua-
litatively poor studies, given that also these studies have a 
certain informative value and the available data are alrea-
dy limited. Given that all studies have been evaluated by 
scientists working in related disciplines and published in 
peer-reviewed journals with impact factor that are listed in 
the common medical databases, reliability of the data and 
an adequate standard may be assumed. Another aspect is 
the frequent measurement of stigmatization by means of 
the Hairdex, a questionnaire addressing quality of life [11]. 
While this is validated as instrument overall and well-ac-
cepted based on the frequent use, the informative value of 
the individual subscales – such as stigmatization – is not 
guaranteed. Furthermore, methodological information, for 
example whether the scores for the subscales were trans-
formed into the standardized range from 0–100, is largely 
missing in the existing literature. If this aspect is viewed in 
connection with the large differences regarding the scores 
for the stigmatization subscale between studies (4.7 [25] 
to 37.8 [28]), it can be assumed that these have no quanti-
tative informative value, either compared with each other 
or separately. Due to the lacking methodological details, 
these scores can only be regarded as a trend. Given that 
this strong limitation applies to four of the eight included 
quantitative surveys, however, this impairs the generaliz-
ation of the presented results. Furthermore, these are the 
only four studies using the same tool for quantification of 
stigmatization and might, therefore, be useful for quanti-
tative comparison.
In conclusion, individuals with hair loss suffer, irrespec-
tive of the specific cause, from internalized and external stig-
matization resulting in massive impairment of their quality 
of life. Despite the resulting high psychological burden for 
the affected individuals, stigmatization is currently asses-
sed only as one of many factors limiting the quality of life. 
Specific studies on the topic of stigmatization due to hair 
loss are rare; longitudinal studies do not exist, although they 
are strongly recommended. Additionally, methodologically 
high-quality and reproducible studies are needed that allow 
comparison between pathogeneses and with other diseases 
with visible changes are required in order to better assess the 
stigmatization and the high psychosocial burden caused by 
hair loss.
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